

CURRICULUM VITAE

Name: Anskar Yu-Hung Leung

Current Appointment: Clinical Professor, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong

Academic Qualifications:

1990: Bachelor of Medical Sciences (B.Med.Sc)
1993: Doctor of Philosophy (The Chinese University of Hong Kong) (Ph.D.) (CUHK)
1996: Bachelor of Medicine and Surgery (with honours) (M.B.,Ch.B.) (Hons)
1999: Member of the Royal Colleges of Physicians of the United Kingdom (M.R.C.P.) (U.K.)
2004: Fellow of the Hong Kong College of Physician (F.H.K.C.P.)
2004: Fellow of the Hong Kong Academy of Medicine (F.H.K.A.M.) (MED)
2006: Doctor of Medicine (The University of Hong Kong) M.D. (HKU)
2009: Fellow of the Royal College of Physicians (Glasgow)
2010: Fellow of the Royal College of Physicians (London)
2010: Fellow of the Royal College of Physicians (Edinburgh)

Specialist Qualification: Specialist in Haematology and Haematological Oncology (Since 2004)

Clinical Training:

1996-1997: Internship	Prince of Wales Hospital, Shatin, HK
1997-2000: Basic Physician Training	Queen Mary Hospital, Pokfulam Road, HK
2000-2003: Haematological Oncology	Queen Mary Hospital, Pokfulam Road, HK

Past Positions held:

1996-1997: House Officer, Prince of Wales Hospital, HK
1997-1999: Medical Officer, Queen Mary Hospital, HK
1999-2008: Assistant Professor, Department of Medicine, HKU
2008-2012: Associate Professor, Department of Medicine, HKU
2008-2015: Assistant Dean (Research), LKS Faculty of Medicine, HKU
2015-2016: Acting Head, Department of Pharmacology and Pharmacy, HKU
2015-2018: Associate Dean (Human Capital), LKS Faculty of Medicine, HKU

Current Positions held:

2012- : Clinical Professor, Department of Medicine, HKU
2014- : Li Shu Fan Medical Foundation Professor in Haematology
2019- : Deputy Head, Department of Medicine, HKU

Honorary Positions held:

1999-2005: Honorary Resident, Queen Mary Hospital, HK
2005-2010: Honorary Associate Consultant, Queen Mary Hospital, HK
2010-: Honorary Consultant, Queen Mary Hospital, HK
2011-2014: Visiting Professor of Shanghai Jiao Tong University Medical School
2017-: Honorary Professor, Peking Union Medical College
2017-: Honorary Consultant, University of Hong Kong – Shenzhen Hospital
2020-: Honorary Consultant, Hong Kong Sanatorium & Hospital

RESEARCH OUTPUT

Publications in international peer reviewed journals

(Based on Scopus, InCites Journal Citation Reports, accessed 3rd October 2020)

First/Corresponding authorship (Contribution > 50%)

Roles: Conception, planning, conduct of experiments (first-authored papers), data analysis, write-up, responses to editors/reviewers and final publication.

1. Tsui SP, Ip HW, Saw NY, Zhang C, Cheung AK, Ng NK, Man CH, Lam SS, Tang WF, Lin CH, Cheng GH, Au CH, Ma ES, Chan TL, So CC, Ng MH, Cheng KC, Wong KF, Siu LP, Yip SF, Lin SY, Lau JS, Luk TH, Lee HK, Lau CK, Kho B, Sim JP, Kwong YL, Leung SY, Javed A, **Leung AY**. Redefining prognostication of *de novo* cytogenetically normal acute myeloid leukemia in young adults. *Blood Cancer Journal* 2020;10(10):104.

Impact Factor: 8.023; **Rank** 6/76 in Haematology; **Citation:** N.A.

2. Guo Y, Cheng BYL, Wang D, Ma ACH, He BL, Man TK, Cheung MPL, Shi X, Ng NKL, **Leung AYH**. Function of Arl4aa in the Initiation of Hematopoiesis in Zebrafish by Maintaining Golgi Complex Integrity in Hemogenic Endothelium. *Stem Cell Reports*. 2020;14(4):575-589.

Impact Factor: 6.032; **Rank** 5/29 in Cell & Tissue Engineering; **Citation:** N.A.

3. He BL, Yang N, Man CH, Ng NK, Cher CY, Leung HC, Kan LL, Cheng BY, Lam SS, Wang ML, Zhang CX, Kwok H, Cheng G, Sharma R, Ma AC, So CE, Kwong YL, **Leung AY**. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. *EMBO Mol Med*. 2020;12(4):e10895.

Impact Factor: 8.821; **Rank** 9/138 in Medicine, Research and Experimental; **Citation:** N.A.

4. Lam SSY, **Leung AYH**. Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML. *Int J Mol Sci*. 2020;21(4). pii: E1537.

Impact Factor: 4.556; **Rank** 74/297 in Biochemistry and Molecular Biology; **Citation:** 4.

5. Leung RKC, Leung HC, **Leung AYH**. Diverse pathogenetic roles of SOX genes in acute myeloid leukaemia and their therapeutic implications. *Semin Cancer Biol*. 2019. pii: S1044-579X(18)30139-1.

Impact Factor: 11.090; **Rank** 14/244 in Oncology; **Citation:** 2.

6. Zhang C, Lam SSY, Leung GMK, Tsui SP, Yang N, Ng NKL, Ip HW, Au CH, Chan TL, Ma ESK, Yip SF, Lee HKK, Lau JSM, Luk TH, Li W, Kwong YL, **Leung AYH**. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. *Cancer*. 2020; 126(2): 344-353.

Impact Factor: 6.126; **Rank** 37/244 in Oncology; **Citation:** 2.

7. Leung GM, Zhang C, Ng NK, Yang N, Lam SS, Au CH, Chan TL, Ma ES, Tsui SP, Ip HW, So CC, Ng MH, Cheng KC, Wong KF, Siu LL, Yip SF, Lin SY, Lau JS, Luk TH, Lee HK, Lau CK, Kho B, Kwong YL, **Leung AY**. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations. *Am J Hematol*. 2019; 94(6): 650-657.

Impact Factor: 6.973; **Rank** 8/76 in Haematology; **Citation:** 12.

8. Lam SS, He AB, **Leung AY**. Treatment of acute myeloid leukemia in the next decade -

Towards real-time functional testing and personalized medicine. *Blood Rev.* 2017;31(6):418-425.

Impact Factor: 5.823; **Rank** 12/76 in Haematology; **Citation:** 7.

9. Lam SY, Ho ES, He BL, Wong WW, Cher CY, Ng NK, Man CH, Gill H, Cheung AM, Ip HW, So CC, Temburini J, So CW, Ho DN, Au CH, Chan TL, Ma ES, Liang R, Kwong YL, **Leung AY**. Homoharringtonine (omacetaxine mepessucinate) as an adjunct for FLT3-ITD acute myeloid leukemia. *Sci Transl Med* 2016; 8(359):359ra129.

Impact Factor: 16.304; **Rank** 2/138 in Medicine: Research & Experimental; **Citation:** 26.

10. Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, **Leung AY**. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. *Blood Cancer J.* 2016; 6(7): e442.

Impact Factor: 8.023; **Rank:** 25/244 in Oncology; **Citation:** 18.

11. Shi X, He BL, Ma AC, **Leung AY**. Fishing the targets of myeloid malignancies in the era of next generation sequencing. *Blood Rev.* 2016;30(2):119-30.

Impact Factor: 5.823; **Rank:** 12/76 in Haematology; **Citation:** 1.

12. Man CH, Fung TK, Wan H, Cher CY, Fan A, Ng N, Ho C, Wan TS, Tanaka T, So EC, Kwong YL, **Leung AY**. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. *Blood.* 2015; 125(25): 3928-3936.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:** 35.

13. Gill H, Man CH, Ip AH, Choi WW, Chow HC, Kwong YL, **Leung AY**. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-Like Tyrosine Kinase-3 internal tandem duplication positive acute myeloid leukemia. *Haematologica.* 2015; 100: e250-e253

Impact Factor: 7.116; **Rank:** 7/76 in Haematology **Citation:** 8.

14. Shi X, He BL, Ma AC, Guo Y, Chi Y, Man CH, Zhang W, Zhang Y, Wen Z, Cheng T, **Leung AY**. Functions of *idh1* and its mutation in the regulation of developmental hematopoiesis in zebrafish. *Blood.* 2015;125(19):2974-84.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:**11

15. Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, **Leung AY**. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. *Blood.* 2014;123(16):2530-9.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:** 24.

16. He BL, Shi X, Man CH, Ma AC, Ekker SC, Chow HC, So CW, Choi WW, Zhang W, Zhang Y, **Leung AY**. Functions of *flt3* in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. *Blood.* 2014;123(16):2518-29.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:** 27.

17. **Leung AY**, Tse E, Hwang YY, Chan TSY, Gill H, Chim CS, Lie AKW, Kwong YL. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor. *Am J Hematol* 2013;88(6):485-91.

Impact Factor: 6.973; **Rank** 8/76 in Hematology; **Citation:** 8.

18. **Leung AY**, Man CH, Kwong YL. FLT3 inhibition: A moving and evolving target in acute myeloid leukaemia. *Leukemia* 2013;27(2):260-8.

Impact Factor: 8.665; **Rank:** 5/76 in Hematology; **Citation:** 80.

19. Chow HC, Cheung AM, Li RA, Chan CW, So EC, **Leung AY**. The use of human induced pluripotent stem cells (hiPSC) for modeling blood disorders. *Drug Discovery Today: Disease Models* 2012;9(4):e185-8.

Impact Factor: 7.321; **Rank:** 12/270 in Pharmacology & Pharmacy; **Citation:** 1.

20. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, **Leung AY**. Sorafenib treatment of FLT3-ITD + acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. *Blood* 2012;119(22):5133-43.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:** 170.

21. Ma AC, Fung TK, Lin RH, Chung MI, Yang D, Ekker SC, **Leung AY**. Methionine aminopeptidase 2 is required for HSC initiation and proliferation. *Blood* 2011;118(20):5448-57.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:** 17.

22. Chung MI, Ma AC, Fung TK, **Leung AY**. Characterization of sry-related hmg box group f genes in zebrafish hematopoiesis. *Exp Hematol* 2011;39(10):986,998.e5.

Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 9.

23. Wong M, Loong F, Khong PL, Kwong YL, **Leung AY**. Mediastinal cryptococcosis masquerading as therapy-refractory lymphoma. *Ann Hematol* 2011;90(5):601-2.

Impact Factor: 2.904; **Rank:** 35/76 in Hematology; **Citation:** 10.

24. Ma AC, Chung MI, Liang R, **Leung AY**. A DEAB-sensitive aldehyde dehydrogenase regulates hematopoietic stem and progenitor cells development during primitive hematopoiesis in zebrafish embryos. *Leukemia* 2010;24(12):2090-9.

Impact Factor: 8.665; **Rank:** 5/76 in Hematology; **Citation:** 19.

25. Fung TK, Chung MIS, Liang R, **Leung AY**. Role of a novel zebrafish nup98 during embryonic development. *Exp Hematol* 2010;38(11):1014,1021.e2.

Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 4.

26. Fung TK, Cheung AM, Kwong YL, Liang R, **Leung AY**. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms. *Leuk Res* 2010;34(10):1390-4.

Impact Factor: 2.241; **Rank:** 51/76 in Hematology; **Citation:** 3.

27. **Leung AY**, Kwong YL. Haematopoietic stem cell transplantation: Current concepts and novel therapeutic strategies. *Br Med Bull* 2010;93(1):85-103.

Impact Factor: 2.835; **Rank:** 45/165 in Medicine, general & internal; **Citation:** 23.

28. Cheung AM, Chow HC, Kwong YL, Liang R, **Leung AY**. FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice. *Leuk Res* 2010;34(1):119-22.
Impact Factor: 2.241; **Rank:** 51/76 in Hematology; **Citation:** 9.
29. Cheung AM, Fung TK, Fan AK, Wan TS, Chow HC, Leung JC, Chan LY, Kwong YL, Liang R, **Leung AY**. Successful engraftment by leukemia initiating cells in adult acute lymphoblastic leukemia after direct intrahepatic injection into unconditioned newborn NOD/SCID mice. *Exp Hematol* 2010;38(1):3-10.
Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 6.
30. Ma AC, Fan A, Ward AC, Liongue C, Lewis RS, Cheng SH, Chan PK, Yip SF, Liang R, **Leung AY**. A novel zebrafish jak2aV581F model shared features of human JAK2V617F polycythemia vera. *Exp Hematol* 2009;37(12):1379-1386.
Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 21.
31. Cheung AMS, Chow HCH, Liang R, **Leung AY**. A comparative study of bone marrow and peripheral blood CD34+ myeloblasts in acute myeloid leukaemia. *Br J Haematol* 2009;144(4):484-91.
Impact Factor: 5.518; **Rank:** 14/76 in Hematology; **Citation:** 12.
32. Ma AC, Chung MI, Liang R, **Leung AY**. The role of survivin2 in primitive hematopoiesis during zebrafish development. *Leukemia* 2009;23(4):712-20.
Impact Factor: 8.665; **Rank:** 5/76 in Hematology; **Citation:** 15.
33. Wong AS, Cheng VC, Yuen KY, Kwong YL, **Leung AY**. High frequency of polyoma BK virus shedding in the gastrointestinal tract after hematopoietic stem cell transplantation: A prospective and quantitative analysis. *Bone Marrow Transplant* 2009;43(1):43-7.
Impact Factor: 4.725; **Rank:** 15/76 in Hematology; **Citation:** 19.
34. Ma AC, Ward AC, Liang R, **Leung AY**. The role of jak2a in zebrafish hematopoiesis. *Blood* 2007;110(6):1824-30.
Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:** 47.
35. Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, Kwong YL, Liang R, **Leung AY**. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. *Leukemia* 2007;21(7):1423-30.
Impact Factor: 8.665; **Rank:** 5/76 in Hematology; **Citation:** 174.
36. Ma AC, Lin R, Chan PK, Leung JCK, Chan LYY, Meng A, Verfaillie CM, Liang R, **Leung AY**. The role of survivin in angiogenesis during zebrafish embryonic development. *BMC Developmental Biology* 2007;7.
Impact Factor: 2.000; **Rank:** 25/41 in Developmental Biology; **Citation:** 37.
37. **Leung AY**, Chow HC, Kwok JS, Lui CK, Cheng VC, Yuen KY, Lie AK, Liang R. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007;39(11):661-5.
Impact Factor: 4.725; **Rank:** 15/76 in Hematology; **Citation:** 15.

38. Wong AS, Chan K-, Cheng VCC, Yuen KY, Kwong YL, **Leung AY**. Relationship of pretransplantation polyoma BK virus serologic findings and BK viral reactivation after hematopoietic stem cell transplantation. *Clinical Infectious Diseases* 2007; 44(6): 830-7.
Impact Factor:8.313; **Rank:** 3/93 in Infectious Diseases; **Citation:** 55.
39. Ma AC, Liang R, **Leung AY**. The role of phospholipase C gamma 1 in primitive hematopoiesis during zebrafish development. *Exp Hematol* 2007;35(3):368-73.
Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 10.
40. Cheung AM, Tam CK, Chow HC, Verfaillie CM, Liang R, **Leung AY**. All-trans retinoic acid induces proliferation of an irradiated stem cell supporting stromal cell line AFT024. *Exp Hematol* 2007;35(1):56-63.
Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 6.
41. **Leung AY**, Liang R. Targeted therapies in T-cell malignancies. *Targeted Oncology* 2007;2(1):39-47.
Impact Factor: 4.036; **Rank:** 88/244 in Oncology; **Citation:** 0.
42. Cheung AM, Kwong YL, Liang R, **Leung AY**. Stem cell model of hematopoiesis. *Current Stem Cell Research & Therapy* 2006;1(3):305-15.
Impact Factor: 2.614; **Rank:** 137/195 in Cell Biology; **Citation:** 8.
43. **Leung AY**, Wong AS, Chan GC, Yuen KY, Kwong YL. Urinary reactivation of polyoma BK virus but not adenovirus in paediatric and adolescent patients after haematopoietic stem cell transplantation. *Bone Marrow Transplant* 2006;37(6):621-3.
Impact Factor: 4.725; **Rank:** 15/76 in Hematology; **Citation:** 7.
44. Kwan TT, Liang R, Verfaillie CM, Ekker SC, Chan LC, Lin S, **Leung AY**. Regulation of primitive hematopoiesis in zebrafish embryos by the death receptor gene. *Exp Hematol* 2006;34(1):27-34.
Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 20.
45. **Leung AY**, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: A changing paradigm. *Bone Marrow Transplant* 2005;36(11):929-37.
Impact Factor: 4.725; **Rank:** 15/76 in Hematology; **Citation:** 108.
46. **Leung AY**, Leung JC, Chan LY, Ma ES, Kwan TT, Lai KN, Meng A, Liang R. Proliferating cell nuclear antigen (PCNA) as a proliferative marker during embryonic and adult zebrafish hematopoiesis. *Histochem Cell Biol* 2005;124(2):105-11.
Impact Factor: 3.418; **Rank:** 108/195 in Cell Biology; **Citation:** 47.
47. **Leung AY**, Liang R. Thrombocytopenia after gemtuzumab is reversible by intravenous immunoglobulin. *Leukemia* 2005;19(6):1077-8.
Impact Factor: 8.665; **Rank:** 5/76 in Hematology; **Citation:** N.A.
48. **Leung AY**, Chan M, Cheng VC, Yuen KY, Kwong YL. Quantification of adenovirus in the lower respiratory tract of patients without clinical adenovirus-related respiratory disease. *Clinical Infectious Diseases* 2005;40(10):1541-4.

Impact Factor: 8.313; **Rank:** 3/93 in Infectious Diseases; **Citation:** 23.

49. **Leung AY**, Chan M, Cheng VC, Lie AK, Yuen KY, Kwong YL. Polyoma BK viruria in patients undergoing autologous hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2005;35(10):1029-30.

Impact Factor: 4.725; **Rank:** 15/76 in Hematology; **Citation:** 13.

50. **Leung AY**, Verfaillie CM. All-trans retinoic acid (ATRA) enhances maintenance of primitive human hematopoietic progenitors and skews them towards myeloid differentiation in a stroma-noncontact culture system. *Exp Hematol* 2005;33(4):422-7.

Impact Factor: 2.820; **Rank:** 39/76 in Hematology; **Citation:** 13.

51. **Leung AY**, Chan M, Kwong YL. Genotyping of the noncoding control region of BK virus in patients with haemorrhagic cystitis after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplant* 2005;35(5):531-2.

Impact Factor: 4.725; **Rank:** 15/76 in Hematology; **Citation:** 6.

52. **Leung AY**, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. *Clinical Infectious Diseases* 2005;40(4):528-37.

Impact Factor: 8.313; **Rank:** 3/93 in Infectious Diseases; **Citation:** 166.

53. **Leung AY**, Mendenhall EM, Kwan TT, Liang R, Eckfeldt C, Chen E, Hammerschmidt M, Grindley S, Ekker SC, Verfaillie CM. Characterization of expanded intermediate cell mass in zebrafish chordin morphant embryos. *Dev Biol* 2005;277(1):235-54.

Impact Factor: 2.895; **Rank:**15/41 in Developmental Biology; **Citation:** 38.

54. **Leung AY**, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R, Kwong YL. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. *Bone Marrow Transplant* 2002;29(6):509-13.

Impact Factor: 4.725; **Rank:** 15/76 in Hematology; **Citation:** 94.

55. **Leung AY**, Yuen KY, Cheng VC, Lie AK, Liang R, Kwong YL. Clinical characteristics of and risk factors for herpes zoster after hematopoietic stem cell transplantation. *Haematologica* 2002;87(4):444-6.

Impact Factor: 7.116; **Rank:** 7/76 in Haematology; **Citation:** 9.

56. **Leung AY**, Chan M, Tang SC, Liang R, Kwong YL. Real-time quantitative analysis of polyoma BK viremia and viruria in renal allograft recipients. *J Virol Methods* 2002;103(1):51-6.

Impact Factor: 1.176; **Rank:** 30/37 in Virology; **Citation:** 81.

57. **Leung AY**, Chim CS, Ho PL, Cheng CC, Yuen KY, Lie AK, Au WY, Liang R, Kwong YL. *Candida tropicalis* fungaemia in adult patients with haematological malignancies: Clinical features and risk factors. *J Hosp Infect* 2002;50(4):316-9.

Impact Factor: 3.271; **Rank:** 37/93 in Infectious Disease; **Citation:** 38.

58. **Leung AY**, Chow HC, Kwong YL, Lie AK, Fung AT, Chow WH, Yip AS, Liang R. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. *Blood* 2001;98(8):2584-7.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:** 58.

59. **Leung AY**, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. *Blood* 2001;98(6):1971-8.

Impact Factor: 17.543; **Rank:** 1/76 in Hematology; **Citation:**190.

60. **Leung AY**, Chim CS, Kwong YL, Lie AK, Au WY, Liang R. Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura in adult Chinese patients: An analysis of 220 cases. *Ann Hematol* 2001;80(7):384-6.

Impact Factor: 2.904; **Rank:** 35/76 in Hematology; **Citation:** 30.

61. **Leung AY**, Kwok J, Lie AK, Chen P, Chen FE, Liang R. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings. *Haematologica* 2001;86(6):652-6.

Impact Factor: 7.116; **Rank:** 7/76 in Haematology; **Citation:** 5.

62. **Leung AY**, Lie AK, Au WY, Hawkins BR, Kwong YL, Liang R. Unmanipulated bone marrow transplantation from one-HLA locus mismatched siblings carries high transplant-related mortality in Chinese patients. *Haematologica* 2001;86(5):518-22.

Impact Factor: 7.116; **Rank:** 7/76 in Haematology; **Citation:** 1.

63. **Leung AY**, Lie AK, Lam CC, Tso WK, Liang R, Kwong YL. Indwelling catheter-related central venous thrombosis during bone marrow transplantation. *Haematologica* 2001;86(3):331-2.

Impact Factor: 7.116; **Rank:** 7/76 in Haematology; **Citation:** 1.

64. **Leung AY**, Lie AK, Kwong YL, Ooi GC, Yau CC, Liang R. The use of autologous stem cell transplantation in the treatment of regionally advanced nasopharyngeal carcinoma. *Haematologica* 2001;86(4).

Impact Factor: 7.116; **Rank:** 7/76 in Haematology **Citation:** N.A.

65. **Leung AY**, Hawkins BR, Chim CS, Kwong YL, Liang RHS. Genetic analysis of HLA-typing in Chinese patients with idiopathic thrombocytopenic purpura. *Haematologica* 2001;86(2):221-2.

Impact Factor: 7.116; **Rank:** 7/76 in Haematology; **Citation:** 4.

66. **Leung AY**, Wong PYD, Yankaskas JR, Boucher RC. cAMP- but not Ca²⁺-regulated Cl⁻ conductance is lacking in cystic fibrosis mice epididymides and seminal vesicles. *American Journal of Physiology - Cell Physiology* 1996;271(1 40-1):C188-93.

Impact Factor: 3.485; **Rank:** 18/81 in Physiology; **Citation:** 35.

67. **Leung AY**, Wong PYD, Gabriel SE, Yankaskas JR, Boucher RC. cAMP- but not Ca²⁺-regulated Cl⁻ conductance in the oviduct is defective in mouse model of cystic fibrosis. *American Journal of Physiology - Cell Physiology* 1995;268(3 37-3):C708-12.

Impact Factor: 3.485; **Rank:** 18/81 in Physiology; **Citation:** 31.

68. **Leung AY**, Wong PYD. Biphasic short-circuit current response to noradrenaline mediated by Ca²⁺ and cAMP in cultured rat epididymal epithelium. *Pflügers Archiv European Journal of Physiology* 1994;426(5):396-401.

Impact Factor: 3.158; **Rank:** 23/81 in Physiology; **Citation:** 13.

69. **Leung AY**, Wong PYD. Ca²⁺ release in cultured rat epididymal cells during hypoosmotic swelling. *Pflügers Archiv European Journal of Physiology* 1993;425(1-2):77-81.

Impact Factor: 3.158; **Rank:** 23/81 in Physiology; **Citation:** 8.

70. **Leung AY**, Tai HL, Wong PYD. ATP stimulates Ca²⁺ release from a rapidly exchanging pool in cultured rat epididymal cells. *American Journal of Physiology - Cell Physiology* 1993;264(6 33-6):C1388-94.

Impact Factor: 3.485; **Rank:** 18/81 in Physiology; **Citation:** 9.

71. **Leung AY**, Wong PYD. Studies of transepithelial Cl⁻ transport in cultured cauda epididymal cells of rats by the short-circuit current method. *J Physiol (Lond)* 1992;457:391-406.

Impact Factor: 4.547; **Rank:** 11/81 in Physiology; **Citation:** 19.

72. **Leung AY**, Yip WK, Wong PYD. Characterization of adrenoceptors involved in the electrogenic chloride secretion by cultured rat epididymal epithelium. *Br J Pharmacol* 1992;107(1):146-51.

Impact Factor: 7.730; **Rank:** 9/270 in Pharmacology and Pharmacy; **Citation:** 20.

73. **Leung AY**, Leung PY, Cheng-Chew SB, Wong PYD. The role of calcitonin gene-related peptide in the regulation of anion secretion by the rat and human epididymis. *J Endocrinol* 1992;133(2):259-68.

Impact Factor: 3.397; **Rank:** 61/143 in Endocrinology and Metabolism; **Citation:** 15.

74. **Leung AY**, Wong PYD. A method for studying apical anion conductance in cultured rat epididymal cells using the short-circuit current technique. *J Physiol (Lond)* 1992;446.

Impact Factor: 4.547; **Rank:** 11/81 in Physiology; **Citation:** N.A.

Co-authorship (Contribution > 5%)

Roles: Conception, planning, contribution to patient samples and management and conduct some of the experiments. Specific contributions highlighted by **asterisks**.

75. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, **Leung AY**, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol.* 2019; 20(7): 984-997. (Impact Factor: 33.752; Citations: 58)

76. Kwok WC, Liang BM, Lui MM, Tam TC, Sim JP, Tse EW, **Leung AY**, Kwong YL, Lie AK, Ip MS, Lam DC. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. *Respirology.* 2019;24(5):459-466. (Impact Factor: 4.880; Citation 7)

77. *Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B, Chan YS, Wei L, Chin SM, Azad A, He AB, **Leung AY**, Yang M, Shyh-Chang N, Cho WC, Shi J and Le MT. Efficient RNA drug delivery using red blood cell extracellular vesicles. *Nat Commun* 2018; 9(1): 2359. (Impact Factor: 12.121; Citation: 66)

* Contribute to the study conception and provision of research materials.

78. *Leung GK, Luk HM, Tang VH, Gao WW, Mak CC, Yu MH, Wong WL, Chu YW, Yang WL, Wong MH, Ma AC, **Leung AY**, Jin DY, Chan KY, Allanson J, Lo IF, Chung BH. Integrating

functional analysis in the next-generation sequencing diagnostic pipeline of RASopathies. *Sci Rep* 2018; 8(1): 2421. (Impact factor: 3.998; Citation: 5)

* Contribute to the training of research staff in zebrafish and led to identification of specific phenotypes in embryos with RAS mutation.

79. Li J, Sim J, **Leung AY**, Kwong YL. Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin. *Ann Hematol.* 2018; 97(3): 551-554. (Impact factor:3.337; Citation:2)

80. Hospital MA, Green AS, Maciel TT, Moura IC, **Leung AY**, Bouscary D, Tamburini J. FLT3 inhibitors: clinical potential in acute myeloid leukemia. *Onco Targets Ther.* 2017;10:607-615. (Impact Factor: 2.612; Citation: 14)

81. Au CH, **Leung AY**, Kwong A, Chan TL, Ma ES. INDELseek: detection of complex insertions and deletions from next-generation sequencing data. *BMC Genomics* 2017;18(1):16. (Impact Factor: 3.594; Citation: 10)

82. Sun XX, Zhou ZL, Man CH, **Leung AY**, Ngan AH. Cell-structure specific necrosis by optical-trap induced intracellular nuclear oscillation. *J Mech Behav Biomed Mater.* 2017;66:58-67. (Impact Factor: 3.372; Citation 3)

83. Lin Q, Zhang Y, Zhou R, Zheng Y, Zhao L, Huang M, Zhang X, **Leung AY**, Zhang W, Zhang Y. Establishment of a congenital amegakaryocytic thrombocytopenia model and a thrombocyte-specific reporter line in zebrafish. *Leukemia.* 2017;31(5):1206-1216. (Impact Factor: 8.865; Citation:5)

84. Hou J, Luo T, Ng KL, **Leung AY**, Liang R, Sun D. Characterization of Drug Effect on Leukemia Cells Through Single Cell Assay With Optical Tweezers and Dielectrophoresis. *IEEE Trans Nanobioscience.* 2016;15(8):820-827. (Impact Factor: 2.771; Citation: 4)

85. Liu W, Wu M, Huang Z, Lian J, Chen J, Wang T, **Leung AY**, Liao Y, Zhang Z, Liu Q, Yen K, Lin S, Zon LI, Wen Z, Zhang Y, Zhang W. c-myc hyperactivity leads to myeloid and lymphoid malignancies in zebrafish. *Leukemia.* 2016; 31(1): 222-233. (Impact Factor: 8.865; Citation:14)

86. Chuncharunee S, Wong R, Rojnuckarin P, Chang CS, Chang KM, Lu MY, Hwang WL, Koh LP, Chen TY, **Leung AY**, Norasetthada L, Wang SC, Chang MC, Wu KH, Issaragrisil S. Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study. *Int J Hematol.* 2016 Jul 104(4):454-61. (Impact Factor; 2.245; Citations: 11)

87. Wan Y, Zhang Q, Zhang Z, Song B, Wang X, Zhang Y, Jia Q, Cheng T, Zhu X, **Leung AY**, Yuan W, Jia H, Fang X. Transcriptome analysis reveals a ribosome constituents disorder involved in the RPL5 downregulated zebrafish model of Diamond-Blackfan anemia. *BMC Med Genomics.* 2016; 9: 13. (Impact Factor: 2.568; Citations: 15)

88. Gill H, **Leung AY**, Kwong YL. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. *Int J Mol Sci.* 2016 Mar 24;17(4):440. (Impact Factor: 4.556; Citations:26)

89. Gill H, **Leung AY**, Kwong YL. Molecularly targeted therapy in acute myeloid leukemia. *Future Oncol.* 2016 Mar;12(6):827-38. (Impact Factor: 2.660; Citations: 6)

90. *Ma MK, **Leung AY**, Lo KY, Lio WI, Chan HW, Wong I, Hau AK, Tam CH, Wong AK, Kuok UI, Chau KF, Fung SK, Kwan TH, Wong SS, Tang SC. Screening Algorithm for BK Virus-Associated Nephropathy Using Sequential Testing of Urinary Cytology: A Probabilistic Model Analysis. *Am J Nephrol.* 2015;42(6):410-7. (Impact Factor: 3.411; Citations: 3) * Contributed to the

design of molecular platform for BK DNA quantification.

- 91.** Gou X, Wang R, Lam SS, Hou J, **Leung AY**, Sun D. Cell adhesion manipulation through single cell assembly for characterization of initial cell-to-cell interaction. *Biomed Eng Online*. 2015;14:114. (Impact Factor: 2.059; Citations:5)
- 92.** *Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, **Leung AY**, Moura IC, Bouscary D, Tamburini J. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. *Sci Adv*. 2015;1(8):e1500221. (Impact Factor: 13.116; Citations: 37) * Contributed to the examination of PIM inhibitor on its effects on AML.
- 93.** Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, Gil J, **Leung AY**, Ashworth A, So CW. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. *Nat Med*. 2015;21(12):1481-90. (Impact Factor: 36.130; Citations: 73)
- 94.** Gill H, **Leung AY**, Chan CC, Lau JS, Chan C, Yip SF, Liu H, Kho B, Mak V, Lee HK, Lin SY, Lau CK, Kwong YL. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis. *Hematology*. 2016;21(1):10-8. (Impact Factor: 1.244; Citations: 2)
- 95.** Hu JJ, Wong NK, Ye S, Chen X, Lu MY, Zhao AQ, Guo Y, Ma AC, **Leung AY**, Shen J, Yang D. Fluorescent Probe HKSOX-1 for Imaging and Detection of Endogenous Superoxide in Live Cells and In Vivo. *J Am Chem Soc*. 2015;137(21):6837-43 (Impact Factor: 14.612; Citations: 134)
- 96.** Yang H, Gou X, Wang Y, Fahmy TM, **Leung AY**, Lu J, Sun D. A dynamic model of chemoattractant-induced cell migration. *Biophys J*. 2015;108(7):1645-51. (Impact Factor: 3.854; Citations: 24)
- 97.** Ma MK, **Leung AY**, Lo KY, Lio WI, Chan HW, Wong I, Hau AK, Tam CH, Wong AK, Kuok UI, Chau KF, Fung SK, Kwan TH, Wong SS, Tang SC. Screening algorithm for BK virus-associated nephropathy using sequential testing of urinary cytology: A probabilistic model analysis. *Am. J. Nephrol*. 2015; 42(6): 410-417. (Impact Factor: 3.441; Citation: 3)
- 98.** *Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, **Leung AY**, Smith CC, Shah NP, Shokat KM. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. *Elife*. 2014 Dec 22;3. (Impact Factor: 7.080; Citations: 25) * Developed zebrafish platform and examined the effects of new FLT3 inhibitor based the model.
- 99.** Gill H, Ip HW, Pang AW, Sum J, **Leung AY**, Kwong YL. FLT3 internal tandem duplication in acute promyelocytic leukemia: central nervous system relapse. *Ann Hematol*. 2015;94(6):1049-51. (Impact Factor: 2.904; Citations: 1)
- 100.** Hu L, Cheng H, Gao Y, Shi M, Liu Y, Hu Z, Xu J, Qiu L, Yuan W, **Leung AY**, Yang YG, Cheng T. Antioxidant N-acetyl-L-cysteine increases engraftment of human hematopoietic stem cells in immune-deficient mice. *Blood*. 2014;124(20):e45-8. (Impact Factor: 17.543; Citations 34)
- 101.** Song B, Zhang Q, Zhang Z, Wan Y, Jia Q, Wang X, Zhu X, **Leung AY**, Cheng T, Fang X, Yuan W, Jia H. Systematic transcriptome analysis of the zebrafish model of diamond-blackfan anemia induced by RPS24 deficiency. *BMC Genomics*. 2014;15:759. (Impact Factor: 3.594; Citations:9)
- 102.** Cheung CY, **Leung AY**, Chan SC, Trendell-Smith NJ, So CC, Kwong YL. Fatal graft-versus-host disease after unrelated cadaveric liver transplantation due to donor/recipient human leucocyte antigen matching. *Intern Med J*. 2014;44(4):425-6. (Impact Factor: 1.677; Citations: 4)

- 103.** Weng Z, Kong CW, Ren L, Karakikes I, Geng L, He J, Chow MZ, Mok CF, Keung W, Chow H, **Leung AY**, Hajjar RJ, Li RA, Chan CW. A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. *Stem Cells Dev.* 2014;23(14):1704-16. (Impact Factor: 3.082; Citations: 65)
- 104.** Lai W, Li Y, Mak S, Ho F, Chow S, Chooi W, Chow CH, **Leung A**, Chan B. Reconstitution of bone-like matrix in osteogenically differentiated mesenchymal stem cell-collagen constructs: A three-dimensional in vitro model to study hematopoietic stem cell niche. *J Tissue Eng.* 2013;4:2041731413508668 (Impact Factor:5.352 , Citations: 18)
- 105.** Gill H, Hwang YY, Chan TS, Pang AW, **Leung AY**, Tse E, Kwong YL. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab. *J Clin Virol.* 2014;59(4):255-8. (Impact Factor: 2.777; Citations: 9)
- 106.** Fung TK, **Leung AY**, So CW. Sox4you: a new player in C/EBP α leukemia. *Cancer Cell.* 2013; 24(5): 557-9. (Impact Factor: 26.602; Citations: 8)
- 107.** Chan TS, Gill H, Hwang YY, Sim J, Tse AC, Loong F, Khong PL, Tse E, **Leung AY**, Chim CS, Lie AKW, Kwong YL. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. *Ann Hematol* 2013:1-6. (Impact Factor: 2.904; Citations: 16)
- 108.** Gou X, Han HC, Hu S, **Leung AY**, Sun D. Applying combined optical tweezers and fluorescence microscopy technologies to manipulate cell adhesions for cell-to-cell interaction study. *IEEE Transactions on Biomedical Engineering* 2013;60(8):2308-15. (Impact Factor: 4.424; Citations: 27)
- 109.** Kwong YL, Pang AW, **Leung AY**, Chim CS, Tse E. Quantification of circulating epstein-barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: Diagnostic and prognostic significance. *Leukemia* 2014; 28(4):865-70. (Impact Factor: 8.865; Citations:75)
- 110.** Hwang YY, Sim J, **Leung AY**, Lie AK, Kwong YL. BK virus-associated bilateral ureteric stenosis after haematopoietic SCT: Viral kinetics and successful treatment. *Bone Marrow Transplant* 2013;48(5):745-6. (Impact Factor: 4.725; Citations: 6)
- 111.** Chan TS, Hwang YY, Gill H, Cheung WW, Tse E, **Leung AY**, Chim CS, Lie AK, Kwong YL. Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital. *Intern Med J* 2013;43(5):541-6. (Impact Factor: 1.677; Citations: 3)
- 112.** Hu S, Gou X, Han H, **Leung AY**, Sun D. Manipulating cell adhesions with optical tweezers for study of cell-to-cell interactions. *Journal of Biomedical Nanotechnology* 2013;9(2):281-5. (Impact Factor: 4.483; Citations:15)
- 113.** *Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG, Krug li RG, Tan W, Penheiter SG, Ma AC, **Leung AY**, Fahrenkrug SC, Carlson DF, Voytas DF, Clark KJ, Essner JJ, Ekker SC. In vivo genome editing using a high-efficiency TALEN system. *Nature* 2012;491(7422):114-8. (Impact Factor: 42.778; Citations: 664) * Contributed to the experiments related to TALEN gene knock out in zebrafish.
- 114.** Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, **Leung AY**, Chim CS. SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia lymphoma study group. *Blood* 2012;120(15):2973-80. (Impact Factor: 17.543; Citations: 226)
- 115.** Lu YC, Chen H, Fok KL, Tsang LL, Yu MK, Zhang XH, Chen J, Jiang X, Chung YW, Ma ACH, **Leung AY**, Huang HF, Chan HC. CFTR mediates bicarbonate-dependent activation of miR-

125b in preimplantation embryo development. *Cell Res* 2012;22(10):1453-66. (Impact Factor: 20.507; Citations: 26)

116. Huang H-, Chen P, Li B-, Fu J-, Li J, Zhang X-, Liu R, Fan Y-, Zhang H, Chow HC, **Leung AY**, Liang R. Influence of rosiglitazone and all-trans-retinoic acid on angiogenesis and growth of myeloma xenograft in nude mice. *Chinese Journal of Oncology* 2012;34(9):652-7 (Impact Factor:N.A.Citations: 2)

117. Chan TS, Hwang YY, Gill H, Au WY, **Leung AY**, Tse E, Chim C-, Loong F, Kwong YL. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: Late onset and favorable response to treatment. *Clin Transplant* 2012;26(5):679-83. (Impact Factor: 1.665; Citations: 13)

118. Yeung CK, **Leung AY**, Trendell-Smith NJ, Kwong YL. Subtle skin infiltration in hepatosplenic $\gamma\delta$ T cell lymphoma. *Histopathology* 2012;61(1):131-2 (Impact Factor: 3.626; Citations: 2)

119. Gill H, Ip AH, Leung R, So JC, Pang AW, Tse E, **Leung AY**, Lie AK, Kwong YL. Indolent T-cell large granular lymphocyte leukaemia after haematopoietic SCT: A clinicopathologic and molecular analysis. *Bone Marrow Transplant* 2012;47(7):952-6. (Impact Factor: 4.725; Citations: 20)

120. Chan GC, **Leung AY**, Wong ASY, Chan KW, Kwong YL, Lai KN, Tang SC. Quantification of BK viral load in asymptomatic renal allograft recipients. *Ren Fail* 2012;34(5):550-4. (Impact Factor: 1.985; Citations: 2)

121. Lee EY, Anthony M-, **Leung AY**, Loong F, Khong PL. Utility of FDG PET/CT in the assessment of myeloid sarcoma. *Am J Roentgenol* 2012;198(5):1175-9. (Impact Factor: 3.013; Citations: 29)

122. Xiao S-, Kung AW, Gao Y, Lau K-, Ma A, Zhang Z-, Liu J-, Xia W, He J-, Zhao L, Nie M, Fu W-, Zhang M-, Sun J, Kwan JSH, Tso GHW, Dai Z-, Cheung C-, Bow CH, **Leung AY**, Tan KC, Sham PC. Post-genome wide association studies and functional analyses identify association of MPP7 gene variants with site-specific bone mineral density. *Hum Mol Genet* 2012;21(7):1648-57. (Impact Factor 5.100; Citations:18)

123. Chan TS, Au WY, Lam K, Lam Y-, So CC, **Leung AY**, Tse E, Lie AK, Kwong YL. Donor cell leukaemia after allogeneic haematopoietic SCT followed by prolonged thalidomide maintenance for multiple myeloma. *Bone Marrow Transplant* 2012;47(4):612-5. (Impact Factor: 4.725; Citation: N.A.)

124. Chan TS, Gill H, **Leung AY**, Chan W-, Khong PL, Kwong YL. Uveitis as the initial manifestation of diffuse large B-cell lymphoma. *Am J Hematol* 2012;87(2):198-200. (Impact Factor: 6.973; Citation:1)

125. Tse HY, Hui MN, Li L, Lee SM, **Leung AY**, Cheng SH. Angiogenic efficacy of simplified 2-herb formula (NF3) in zebrafish embryos in vivo and rat aortic ring in vitro. *J Ethnopharmacol* 2012;139(2):447-53. (Impact Factor: 3.690; Citations: 12)

126. Lee EY, **Leung AY**, Anthony M-, Loong F, Khong PL. Utility of 18F-FDG PET/CT in identifying terminal ileal myeloid sarcoma in an asymptomatic patient. *Am J Hematol* 2011;86(12):1036-7. (Impact Factor: 6.973; Citation: 1)

127. Lam DC, Lam B, Wong MK, Lu C, Au WY, Tse EW, **Leung AY**, Kwong YL, Liang RHS, Lam WK, Ip MSM, Lie AKW. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study. *Bone Marrow Transplant*

2011;46(12):1551-6. (Impact Factor: 4.725; Citations: 43)

128. Gill H, Chim CS, Au WY, Loong F, Tse E, **Leung AY**, Kwong YL. Non-gastric marginal zone B cell lymphoma: Clinicopathologic features and treatment results. *Ann Hematol* 2011;90(12):1399-407 (Impact Factor: 2.904; Citations:12).

129. Tse E, **Leung AY**, Sim J, Lee HK, Liu HS, Yip SF, Kwong YL. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. *Ann Hematol* 2011;90(11):1277-81. (Impact Factor: 2.904; Citations: 15)

130. Gu J, Chan T, Zhang J, **Leung AY**, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: The added value to whole-body MRI at initial diagnosis of lymphoma. *Am J Roentgenol* 2011;197(3):W384-91. (Impact Factor: 3.013; Citations: 93)

131. Tan Y, Fung TK, Wan H, Wang K, **Leung AY**, Sun D. Biophysical characterization of hematopoietic cells from normal and leukemic sources with distinct primitiveness. *Appl Phys Lett* 2011;99(8). (Impact Factor: 3.597; Citations: 27)

132. Hwang YY, **Leung AY**, Lau WH, Loong F, So JC, Tse E, Kwong YL. Synchronous Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-barr virus-positive classical Hodgkin lymphoma. *Histopathology* 2011;59(2):352-5. (Impact Factor: 3.626; Citations: 2)

133. Tan Y, **Leung AY**, Wang K, Fung TK, Sun D. Optical tweezer technology: Nanomechanical characterization of myeloblasts from cancer patients with optical tweezers. *IEEE Nanotechnology Magazine* 2011;5(1):17-21 (Impact Factor: N.A.; Citations: 4)

134. Yap DY, Leung CC, Hwang GY, **Leung AY**, Chan GS, Chan KW, Tang SC. Pyrexia of unknown origin and proteinuria: An enigma solved by renal biopsy. *Nephrology* 2011;16(2):249-50.(Impact Factor:1.749; Citations: N.A.)

135. Kwong YL, **Leung A**, Cheung RT. Pregabalin-induced trismus in a leukemia patient. *Journal of Hospital Medicine* 2011;6(2):103-4. (Impact Factor: 2.194; Citations: 5)

136. Chan WK, Au WY, Wong CO, Liang R, **Leung AY**, Kwong YL, Khong PL. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B-and T-cell lymphomas. *Clin Nucl Med* 2010;35(8):571-5. (Impact Factor: 6.587; Citations: 41).

137. Au WY, Lam KK, **Leung AY**, Liang R, Lie AK, Kwong YL. Occult autologous haematopoietic regeneration without disease relapse following myeloablative allogeneic haematopoietic SCT for lymphomas. *Bone Marrow Transplant* 2010;45(8):1377-8. (Impact Factor: 4.725; Citation: N.A.)

138. Gill HH, Lau WH, Chan AC, Leung RY, Khong PL, **Leung AY**, Kwong YL. CD20 expression in natural killer T cell lymphoma. *Histopathology* 2010;57(1):157-9. (Impact Factor: 3.626; Citations: 14)

139. Gill HH, **Leung AY**, Trendell-Smith NJ, Yeung CK. Sweet syndrome due to myelodysplastic syndrome: Possible therapeutic role of intravenous immunoglobulin in addition to standard treatment. *Advances in Hematology* 2010; 2010:328316 (Impact Factor: N.A.;Citation: 12)

140. Kwong YL, Au WY, **Leung AY**, Tse EW. T-cell large granular lymphocyte leukemia: An asian perspective. *Ann Hematol* 2010;89(4):331-9. (Impact Factor: 2.904; Citations: 22)

141. Yeung CK, Cheung WW, **Leung AY**, Kwong YL. Spontaneous central venous catheter fracture: Relevance of the pinch-off sign. *Journal of Hospital Medicine* 2010;5(4). (Impact Factor: 2.194; Citation: 2)

142. Cheng VC, Chan JF, Ngan AH, To KK, Leung SY, Tsoi HW, Yam WC, Tai JW, Wong SS, Tse

H, Li IW, Lau SK, Woo PC, **Leung AY**, Lie AK, Liang R, Que TL, Ho PL, Yuen KY. Outbreak of intestinal infection due to rhizopus microsporus. *J Clin Microbiol* 2009;47(9):2834-43. (Impact Factor: 5.897; Citations: 87)

143. Huang H, Wu D, Fu J, Chen G, Chang W, Chow HC, **Leung AY**, Liang R. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. *Eur J Haematol* 2009;83(3):191-202. (Impact Factor: 2.220; Citations: 11)

144. Hwang YY, **Leung AY**, Ng IO, Chan GSW, Chan K-, Tse E, Kwong YL. Protein-losing enteropathy due to T-cell large granular lymphocyte leukemia. *Journal of Clinical Oncology* 2009;27(12):2097-8. (Impact Factor: 32.956; Citations: 4)

145. Hwang YY, Cheung WW, **Leung AY**, Tse E, Au WY, Kwong YL. Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy. *Leukemia* 2009;23(4):800-1. (Impact Factor: 8.865; Citations: 8)

146. Au WY, **Leung AY**, Tse EW, Cheung WW, Shek TW, Kwong YL. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. *Leuk Res* 2008;32(4):547-51. (Impact Factor: 2.214; Citations: 16)

147. Lam HW, Lin HC, Lao SC, Gao JL, Hong SJ, Leong CW, Yue PY, Kwan YW, **Leung AY**, Wang YT, Lee SM. The angiogenic effects of angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. *J Cell Biochem* 2008;103(1):195-211. (Impact Factor: 4.237; Citations: 80)

148. Tse E, Chan JC, Pang A, Au WY, **Leung AY**, Lam CC, Kwong YL. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. *Leukemia* 2007;21(10):2225-6. (Impact Factor: 8.865; Citations: 20)

149. Cheung WW, Tse E, **Leung AY**, Yuen KY, Kwong YL. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. *Am J Hematol* 2007;82(2):108-11. (Impact Factor: 6.973; Citations: 19)

150. Hui C, Cheung WW, Zhang H, Au W, Yueng Y, **Leung AY**, Leung N, Luk JM, Lie AK, Kwong Y, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. *Gastroenterology* 2006;131(1):59-68. (Impact Factor: 17.373; Citations: 374)

151. Hui CK, Lie A, Au WY, **Leung YH**, Ma SY, Cheung WW, Zhang H-, Chim CS, Kwong YL, Liang R, Lau GK. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. *Blood* 2005;106(2):464-9. (Impact Factor: 17.543; Citations: 57)

152. Hui CK, Lie AK, Au WY, Ma SY, **Leung YH**, Zhang H-, Sun J, Cheung WW, Chim CS, Kwong YL, Liang R, Lau GK. Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. *American Journal of Transplantation* 2005;5(6):1437-45. (Impact Factor: 7.338; Citations: 40)

153. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, **Leung AY**, Tse E, Yau CC, Liang R, Kwong YL. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the world health organization classification scheme: A single center experience of 10 years. *Annals of Oncology* 2005;16(2):206-14. (Impact Factor: 18.274; Citations: 180)

154. Kwok JS, **Leung AY**, Lie AK, Lee TL, Lau YL, Chu P, Jones B, Hawkins B, Liang R.

Antirecipient helper and cytotoxic T-cell frequencies in bone marrow transplantation. *Bone Marrow Transplant* 2004;34(3):207-13. (Impact Factor: 4.725; Citations: 5)

155. Ma SY, Au WY, Lie AK, Ng IO, **Leung AY**, Tse EW, Liang R, Lau GK, Kwong YL. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2004;34(1):57-61. (Impact Factor: 4.725; Citations: 9)

156. Chim CS, Loong F, **Leung AY**, Tsang J, Ooi GC. Primary follicular lymphoma of the small intestine. *Leukemia and Lymphoma* 2004;45(7):1463-6. (Impact Factor: 2.969; Citations: 13)

157. Chim CS, **Leung AY**, Ooi GC. Bull's neck in Hodgkin's disease: A CT imaging appraisal. *Haematologica* 2004;89(5):EIM11. (Impact Factor: 7.116; Citation:N.A.)

158. Ma SY, Au WY, Ng IO, Lie AK, **Leung AY**, Liang R, Lau GK, Kwong YL. Hepatic graft-versus-host disease after hematopoietic stem cell transplantation: Clinicopathologic features and prognostic implication. *Transplantation* 2004;77(8):1252-9. (Impact Factor: 4.264; Citations: 34)

159. Ma SY, Au WY, Chim CS, Lie AK, Lam CC, Tse E, **Leung AY**, Liang R, Kwong YL. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. *Br J Haematol* 2004;124(6):754-61. (Impact Factor: 5.518; Citations: 42)

160. Au WY, Wong RW, Wong BC, Lie AK, Liang R, **Leung AY**, Kwong YL. Reduced incidence of acute graft versus host disease (GVHD) of the gut in Chinese carriers of helicobacter pylori during allogeneic bone marrow transplantation. *Ann Hematol* 2004;83(1):34-7. (Impact Factor: 2.904; Citations: 5)

161. Au WY, Lie AK, Siu LL, Chan EC, Ooi GC, **Leung AY**, Liang R, Kwong YL. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor. *Ann Hematol* 2003;82(9):548-51. (Impact Factor: 2.904; Citations: 1)

162. Ma SY, Au WY, Ng IO, Lie AK, **Leung AY**, Liang RH, Lau GK, Kwong YL. Role of liver biopsy in the management of liver dysfunction after hematopoietic stem-cell transplantation in a hepatitis B virus-prevalent patient population. *Transplantation* 2003;76(1):169-76. (Impact Factor: 4.264; Citations: 12)

163. Au WY, Chan EC, Lie AK, Liang R, **Leung AY**, Ma SK, Kwong YL. Poor engraftment after allogeneic bone marrow transplantation: Role of chimerism analysis in treatment and outcome. *Ann Hematol* 2003;82(7):410-5. (Impact Factor: 2.904; Citations: 6)

164. Li YH, Ma SK, Wan TSK, Au WY, Fung LF, **Leung AY**, Lie AK, Chan LC. Lineage-specific differences in telomere length after bone marrow transplantation. *Bone Marrow Transplant* 2002;30(7):475-7. (Impact Factor: 4.725; Citations: 5)

165. Lo JW, **Leung AY**, Huang XR, Lie AKW, Metz C, Bucala R, Liang R, Lan HY. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients. *Bone Marrow Transplant* 2002;30(6):375-80. (Impact Factor: 4.725; Citations: 18)

166. Lau GK, **Leung YH**, Fong DYT, Au WY, Kwong YL, Lie AK, Hou J, Wen Y, Nanj A, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell

transplantation. *Blood* 2002;99(7):2324-30. (Impact Factor: 17.543; Citations: 166)

167. Choi IC, Fung PC, **Leung AY**, Lie AK, Liang R. Plasma nitric oxide is associated with the occurrence of moderate to severe acute graft-versus-host disease in hemopoietic stem cell transplant recipients. *Haematologica* 2001;86(9):972-6. (Impact Factor: 7.116; Citations: 17)

168. Au WY, Lie AK, Ma SK, Wan TS, Liang R, **Leung YH**, Kwong YL. Philadelphia (ph) chromosome-positive chronic myeloid leukaemia relapsing as ph-negative leukaemia after allogeneic bone marrow transplantation. *Br J Haematol* 2001;114(2):365-8. (Impact Factor: 5.518; Citations: 10)

169. Au WY, Lie AK, Ma SK, **Leung YH**, Siu LL, Kwong YL. Therapy-related myelodysplastic syndrome of recipient origin after allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. *Br J Haematol* 2001;112(2):424-6. (Impact Factor: 5.518; Citations: 20)

170. Huang SJ, **Leung AY**, Fu WO, Chung YW, Zhou TS, Chan PS, Wong PY. Electrophysiological studies of anion secretion in cultured human epididymal cells. *J Physiol (Lond)* 1992;455:455-69 (Impact Factor: 4.547; Citations: 18)

171. Wong PY, Huang SJ, **Leung AY**, Fu WO, Chung YW, Chan PS. Human epididymal cells respond to adrenaline by increase in short-circuit current and whole-cell chloride current. *J Physiol (Lond)* 1992;446. (Impact Factor: 4.547; Citation: N.A.)

Scholarly books and chapters

1. Gill H and **Leung AY**. Polycythaemia Vera – current management and emerging treatment. In: *Polycythemia Vera – Symptoms, Diagnosis and Emerging Treatment*. Nova Science Publishers, NY, USA

2. Fung TK, **Leung AY**, So CW. The Wnt/beta-catenin pathway as a potential target for drug resistant leukemia stem cells. *Stem Cells and Cancer Stem Cells*. M.A. Hayat ed, Springer (In press).

3. Ma AC, Guo Y, He AB and **Leung AY**. Chapter 7: Modeling tumor angiogenesis with zebrafish. In: *Vasculogenesis and angiogenesis – from embryonic development to regenerative medicine*, Simionescu DT and Simionescu A ed. InTech. Croatia. 2011, pp133-144.

3. Wookey PJ, Zulli A, Lo C, Hare DL, Schwarer AP, Darby IA, **Leung AY**. Calcitonin receptor (CTR) expression in embryonic, foetal and adult tissues: developmental and pathophysiological implications. In: “The calcitonin gene-related peptide family; form, function and future perspectives”, Debbie L Hay & Ian M Dickerson ed. Springer, the Netherlands. 2009, pp199-233.

4. Cheung AM, Kwong YL, Liang R and **Leung AY**. Leukemia stem cells in acute myeloid leukemia: current concepts and future challenges. In: *Cancer stem cells* (Guan XY ed). Transworld Research Network. Kerala, India. 2010, pp17-35

5. **Leung AY** and Verfaillie CM. Chapter 17: Stem Cell Model of Hematopoiesis. In: *Hematology Basic Principles and Practice*. Hoffman R ed Churchill Livingstone 4th Edition, Pennsylvania, USA. 2005, pp 200-214.

6. **Leung AY** and Wong PYD. Epididymis as a chloride-secreting organ. CUHK Press, Hong Kong. 1993.

International Conference Papers

1. Ng KL, Lynn C, Leung TW, So CW, **Leung AY**. Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD)-a Mechanistic Study. December 7 - 10, 2019. 61st American Society of Hematology Annual

Meeting, Florida, USA.

2. Man CH, Scadden DT, Mercier F, Liu N, Dong W, Stephanopoulos G, Jiang L, Jung Y, Lin C and **Leung AY**. Epigenetic Activation of the pH Regulator MCT4 in Acute Myeloid Leukemia Exploits a Fundamental Metabolic Process of Enhancing Cell Growth through Proton Shifting. December 7 - 10, 2019, 61st American Society of Hematology Annual Meeting, Florida, USA.
3. Tsui SP, Ip HW, Zhang C, Tang WF, Lin CH, Cheung A, Cheng G, So CC, Leung SY, Au CH, Ma ES, Chan TL, Ng MH, Cheng KC, Wong KF, Siu LL, Yip SF, Lin SY, Lau JS, Luk TH, Lee HK, Lau CK, Kho B, Kwong YL, Javed A, **Leung AY**. A Mutation Pentad Defined Outcome of De Novo and Cytogenetically Normal Acute Myeloid Leukaemia in Young Adults, December 7 - 10, 2019, 61st American Society of Hematology Annual Meeting, Florida, USA.
4. Zhang C, Leung GM, Tsui SP, Ip HW, Ma ES, Au CH, Chan TL, Ng KL, Yip SF, Kho B, Lee HK, Liu Q, Leung TW, Kwong YL, **Leung AY**. A phase II single-arm open-labeled study evaluating combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in newly diagnosed or relapsed/refractory AML carrying FLT3-ITD. 61st American Society of Hematology Annual Meeting, December 7 - 10, 2019, Florida, USA.
5. Cheng BY, Wang DD, He BL, **Leung AY**. A novel zebrafish platform for deciphering the mutations co-operation in driving acute myeloid leukaemia. ZPPM-Zebrafish for Personalized/Precision Medicine Conference, Sept 18 – 20, 2019, Toronto, Canada.
6. Tsui SP, Tang WF, Ip HW, So CC, Au CH, Ma ES, Chan TL, Ng MH, Cheng KC, Wong KF, Siu LL, Yip SF, Lin SY, Lau JS, Luk TH, Lee HK, Lau CH, Kho B, Zhang C, Kwong YL, **Leung AY**. Characterization of Genomic Landscape and Risk Stratification of De Novo Cytogenetically Normal Acute Myeloid Leukaemia. December 1-4, 2018, 60th American Society of Hematology Annual Meeting, San Diego, USA.
7. He BL, Ng N, Cher CY, To A, Zhang C, Lam S, **Leung AY**. Dysregulation of Follistatin Promotes Leukemogenesis in Acute Myeloid Leukemia. 59th ASH Annual meeting, 9-12 December, 2017, Atlanta, USA.
8. Cher CY, Ng N, Lam SS, He BL, Ying D, Chung BH, Au CH, Chan TL, Ma EK, Liang R, Kwong YL, **Leung AY**. Whole exome sequencing identified candidate gene mutations in a pedigree of familial myeloproliferative neoplasm. ISEH 46th Annual Scientific Meeting, 24-27 August, 2017. Frankfurt, Germany.
9. Cheng BY, He BL, Li L, **Leung AY**. A novel functional screening platform using zebrafish model for the study of genetic mutations co-operation in AML. ISEH 46th Annual Scientific Meeting, 24-27 August, 2017. Frankfurt, Germany.
10. He BL, Lam SS, Cher CY, Ng KL, Wong HW, **Leung AY**. Follistatin is a critical mediator for FLT3/ITD+ AML. ISEH 45th Annual Scientific Meeting, 25-28 August 2016. San Diego, USA.
11. He BL, Lam SS, Cher CY, Ng KL, Wong HW, Guo YH, Ma AC, **Leung AY**. Novel therapeutic targets in FLT3/ITD+ acute myeloid leukemia. The 2nd Zebrafish for Personalize/Precision Medicine Conference, 23-26 September 2015. Toronto, Canada.
12. Gill H, Lie AK, Kwong YL and **Leung AY**. Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL. December, 2015.
13. Lam SY, Cher CY, Ng KL, Man CH, **Leung AY**. Whole exome sequencing of FLT3-ITD sorafenib-resistant acute myeloid leukaemia. 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL. December, 2015.
14. Man TK, **Leung AY**, Ma AC. The Role of Calreticulin (Calr) in Vertebrate Hematopoiesis. 8th Zebrafish Disease Model Conference, Boston MA, 2015.
15. He BL, Ma, AC, **Leung AC**. Crosstalk between FLT3/ITD Mutation and the Cellular Morphogens. ISEH 43rd Annual Scientific Meeting, 21-24 August 2014. Montreal, Canada.

16. Guo YH, Ma AC, He BL, Shi XG and **Leung AY**. A novel role of ADP-ribosylation factor like 4aa (arl4aa) in zebrafish hematopoiesis. ISEH 43rd Annual Scientific Meeting, 21-24 August 2014. Montreal, Canada.
17. Lam SS, Cher CY, Ng KL, Man CH, Ho ES, Chow HC, Eaves CJ, Cheung AM, **Leung AY**. Development of a clinically relevant in vitro drug screening platform for chemo-refractory AML patients. 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA. December, 2014.
18. Shi X, He B, Ma AC, Guo Y, **Leung AY**. Functions of idh1 and its mutation in the regulation of embryonic developmental hematopoiesis in zebrafish. ISEH 43rd Annual Scientific meeting, Montreal, Canada, 2014.
19. Man CH, Cher CY, Lam SS, Ho ES, Ng KL and **Leung AY**. Novel Therapeutic Strategy Targeting NHE1 and Its Upstream Activators in Acute Myeloid Leukemia. 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA. December, 2014.
20. Ho ES, Lam SS, Man CH, Cher CY, Kwong YL and **Leung AY**. Bringing an Old Drug to a New Treatment Strategy in Treating FLT-ITD AML - Combination of Homoharringtonine and Sorafenib. 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA. December, 2014.
21. Cher CY, Man CH, Lam SS, Ho ES, Ng KL, Hospital MA, Tamburini J and **Leung AY**. Targeting Polo-like Kinase in Acute Myeloid Leukemia. 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA. December, 2014.
22. He BL, Shi XG, Ma AC, **Leung AY**. A zebrafish model of FMS-like tyrosine kinase 3 (flt3) in normal and malignant hematopoiesis. ISEH 42nd Annual Scientific Meeting, 22-25 August 2013. Vienna, Austria.
23. Shi X, He B, Guo Y, Ma AC, Wong NS, **Leung AY**. The role of inka1b in zebrafish primitive hematopoiesis. ISEH 42nd Annual Scientific meeting, 22-25 August 2013, Vienna, Austria.
24. He BL, Ma AC, **Leung AC**. The role of FLT3 during early hematopoiesis in zebrafish model. The 5th Annual Zebrafish Disease Models Meeting. 16-20 April 2012. Suzhou, China.
25. Man CH, Lam SS, Sun MK, Han HH, Chow HC, Cheung AM, Kwong YL and **Leung AY**. A Novel Role of Tescalcin-Sodium/Hydrogen Exchange Axis Underlying Sorafenib Resistance In FLT3-ITD+ AML. 55th American Society of Hematology (ASH) Annual Meeting and Exposition, New Orleans, Louisiana, December 2013.
26. Ho ES, Chow CH, Chan CT, Luo R, Leung HC, Yiu SM, Chin FY, Kwong YL and **Leung AY**. Whole Genome Sequencing On Donor Cell Leukemia in a Patient with Multiple Myeloma Identified Gene Mutations That May Provide Insights to Leukemogenesis. 54th American Society of Hematology (ASH) Annual Meeting and Exposition, Atlanta, GA, December 2012.
27. Ma AC, Lin RH, Chung MI, Yan D, Liang R and **Leung AY**. Methionine aminopeptidase 2 (MetAP2) is required for zebrafish hematopoietic stem cell initiation, 7th European Zebrafish Meeting, 2011.
28. Chung IS, Ma AC, Fung TK and **Leung AY**. The role of Sox genes (Group F) in zebrafish hematopoiesis, ISEH 39th Annual Scientific Meeting, Melbourne, Australia, 2010.
29. Wong NS, Ma AC and **Leung AY**. The role of the specific aldehyde dehydrogenase (aldh) isoforms in the regulation of embryonic hematopoiesis, 8th ISSCR Annual Meeting, 2010.
30. Fung TK, Fan KP, Wan H, Chow HC, Wong AS, Wan TS, Kwong YL, Liang R and **Leung AY**. Downregulation of SOX7 by DNA methylation and its tumor suppressing role in acute myeloid leukemia, 52nd Annual Meeting of the ASH, Orlando, 2010.
31. Ma AC, Lin H, Chung IS, Yang D, Liang R and **Leung AY**. Distinctive functions of methionine aminopeptidase II in embryonic hematopoiesis in zebrafish embryos., ISEH 39th Annual Scientific Meeting, 2010
32. **Leung AY**, Ma AC, and Ward AC. Expression of Aldehyde Dehydrogenase (ALDH) isoforms

in acute myeloid leukemia, ISEH 38th Annual Scientific Meeting, Greece, 2009.

33. Chan S, Chan S, Lam C, **Leung AY**, Leung D, Lam TH, Johnston J, Chu D, Chan CK, Hung IF, Liang R and Yuen KY. Evaluating a low intensity health education intervention on pneumococcal vaccination uptake among elders with chronic illness., 20th National Conference on Chronic Disease Prevention and Control. Maryland, USA, 2009.

34. Au WY, Tam SC, **Leung AY**, Tse E, Kumana C and Kwong YL. Treatment of relapsed acute promyelocytic leukemia with oral arsenic trioxide: An eleven-year experience, 50th Annual Meeting of the ASH, San Francisco, 2008.

35. Cheung AM, Chow HC, Kwong YL, Liang R and **Leung AY**. Genetic and functional comparison of primitive CD34+ leukemic cells that reside in the marrow compartment and in circulation, 2007 Shanghai International Symposium on Stem Cell Research, 2007

36. Tang SC, **Leung AY**, Chan DT, Lo WK, Kwong YL and Lai KN. BK viral load in renal transplant recipients without clinical nephropathy, Proceedings of the World Transplant Congress. 2008.

37. Chan CF, **Leung AY**, Chan YS and Cheung RT. Central administration of granulocyte- colony stimulating factor in a mice middle cerebral artery occlusion stroke model reduces infarct volume and improves functional outcome, Soc. Neuroscience Abstract (U.S.A.): 598.1. 2007.

38. Chan CF, **Leung AY**, Chan YS and Cheung RT. Intracerebral injection of granulocyte-colony stimulating factor reduces infarct volume following transient middle cerebral artery occlusion in mice, Proceedings of 2nd International Symposium on Healthy Aging - Meeting the Challenges of an Aging Population: 57. March 3-4. 2007.

39. Ma AC, Ward AC, Liang R and **Leung AY**. The study of Jak2V617F mutation in polycythemia vera with zebrafish model. 2007 Shanghai International Symposium on Stem Cell Research, 2007.

40. Hui CK, Cheung WW, Zhang H, Au WY, Yueng YH, **Leung AY**, Leung N, Luk JMC, Lie AK, Kwong YL, Liang R and Lau G. Rituximab increases the Risk of De Novo hepatitis B infection in Hepatitis B Surface Antigen Negative Patients Undergoing Cytotoxic Chemotherapy, J Gastroenterol and Hepatol. 2006, 21(2): A73.

41. Ma AC, Liang R and **Leung AY**. The role of survivin-2 in primitive hematopoiesis during zebrafish development. The 3rd Annual conference of OOTR Neoadjuvant and Molecular Therapy in Cancer, 2006.

42. Huang HW, Wu DP, **Leung AY**, Liang R and Lie AK. Ex vivo anti-tumor activity of rosiglitazone on multiple myeloma cells, 48th Annual Meeting of the ASH, Orlando, 2006.

43. **Leung AY**, Ma AC, Meng AM, Verfaillie CM and Liang R. The role of survivin in angiogenesis during zebrafish embryonic development, 48th Annual Meeting of the ASH, Orlando, 2006.

44. Lie AK, **Leung AY** and Liang R. Allogenic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in Queen Mary Hospital – A single centre experience, 32nd Annual Meeting of the American Society for Bone and Marrow Transplantation, Honolulu, 2006.

45. **Leung AY**. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a Changing paradigm, Roche Asian Transplantation and Immunology Forum, Jeju, Korea. 2005.

46. Au WY, Chim JC, Lie AK, **Leung AY**, Tse EW, Ma SY, Liang R, Pang AW, Kumana CR and Kwong YL. Treatment of relapsed acute promyelocytic leukemia by arsenic-based strategies without hematopoietic stem cell transplantation in Hong Kong: a seven-year experience, American Society of Haematology Annual Scientific Meeting. 2004.

47. Lie A.K.W., Au W.Y., Ma S.Y., **Leung A.Y.H.**, Tse E.W.C., Chan G.C.F., Ha S.Y., Lau Y.L., Kwong Y.L. and Liang R.H.S., Haemopoietic stem cell transplantation in Hong Kong – 14 years of experience at Queen Mary Hospital, 10th Congress of the International Society of hematology, Asian Pacific Division, Nagoya, Japan. Nagoya, Japan, 2004.

48. Lu K.H., Liang R.H.S., Kwong Y.L., Lie A.K.W. and **Leung A.Y.H.**, A single centre, randomized trial on harvest cell yield and marrow engraftment using haemopoietic growth-factor primed bone marrow, Tandem BMT 2004 meeting, Orlando, 2004.
49. Ma SY, Au WY, Lie AK, Tse E, **Leung AY**, Kwong YL and Liang R. A prospective randomized trial of meropenem versus imipenem/cilastatin as monotherapy for neutropenic fever during early phase post stem cell transplantation, 45th Annual Meeting of ASH, San Diego, 2003.
50. Lie AK, Ma SY, Au WY, Ng IO, **Leung AY**, Liang R, Lau GK and Kwong YL. Hepatic graft-versus-host disease after hematopoietic stem cell transplantation: Clinicopathologic features and prognostic implication, 45th Annual Meeting of ASH, San Diego, 2003.
51. **Leung AY**, Ekker SC and Verfaillie CM. Characterization of expanded hematopoietic cells in the intermediate cell mass of the chordin morphants generated by anti-sense morpholino. 45th Annual Meeting of ASH, San Diego, 2003.
52. **Leung AY**, Ekker SC and Verfaillie CM. Differential gene expression of zebrafish chordin morphants with special reference to the mechanism of hematopoietic cell proliferation in developing embryos. 45th Annual Meeting of ASH, San Diego, 2003.
53. Au WY, Pang AW, Chim JC, Lie AK, **Leung AY**, Liang R and Kwong YL. Quantification of circulating Epstein-Barr Virus (EBV) DNA in the monitoring of EBV related lymphoid malignancies, *Annals Oncol.* 2002, 13 (Supp2) 66: 219.
54. **Leung AY** and Verfaillie CM All-trans retinoic acid (ATRA) preserves primitive human progenitors but blocks erythroid, platelet and NK differentiation. 44th Annual Meeting of the American Society of Hematology, Philadelphia, 2002.
55. Li YH, Wan TS, Chan LC, Fung LF, Lie AK, Au WY, **Leung AY**, Chan KL and Ma ES. Variable telomere shortening in different white cell compartments after allogeneic bone marrow transplantation (BMT), Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, USA, March 2002.
56. **Leung AY**, Eckfeldt CE and Liu EH. Differential Gene Expression of Primitive Hematopoietic Stem/Progenitor Cells Derived from Human Umbilical Cord Blood, 44th Annual Meeting of American Society of Hematology 2002.
57. Ma ES, Li YH, Wan TS, Au WY, Fung LF, **Leung AY**, Lie AK and Chan LC. Telomere shortening in blood leucocytes after bone marrow transplantation is mainly contributed by the T-suppressor compartment, Proceedings of the 7th Annual Meeting of the European Haematology Association, Florence, Italy, 6-9 June 2002.
58. **Leung AY**, Suen CK, Lie AK, Liang R, Yuen KY and Kwong YL. Quantification of polyoma BK viruria to predict the occurrence of hemorrhagic cystitis in bone marrow transplantation patients., Annual Meeting of American Society for Blood and Marrow Transplantation. Keystone, USA.. 2001.
59. **Leung AY**, Suen C, Chow CH, Liang R, Lie AK and Kwong YL. Quantitative and genotypic analysis of polyoma BK viruria during hemorrhagic cystitis complicating bone marrow transplantation., 43rd Annual Meeting of American Society of Hematology, Orlando, USA.. 2001.
60. **Leung AY**, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R and Kwong YL. Clinicopathological features and risk factors of severe haemorrhagic cystitis complicating bone marrow transplantation., National Marrow Donor Program Council Meeting. Minneapolis, USA. 2001.
61. **Leung AY**, Chen FE, Lie AK, Chen P, Kwok JS and Liang R. Helper T-lymphocyte precursor frequency (HTLPf) predicts the occurrence of graft-versus-host disease (GVHD) after allogeneic bone marrow transplant. 37th Annual Meeting of the American Society of Clinical Oncology. 2001.
62. Au WY, Lie AK, Kwong YL, Lee CK, Chim JC, **Leung AY** and Liang R. Donor Lymphocyte Infusion (DLI) for leukemia relapse: The Queen Mary Hospital Experience, The 4th Joint Shanghai-Hong Kong Haematology Meeting. 2000.
63. Au WY, Lie AK, Lee CK, **Leung AY**, Liang R and Kwong YL. ICE chemotherapy plus

peripheral blood stem cell (PBSC) for post-BMT relapse of leukemia. International Society of Hematology. 2000.

64. Au WY, Lie AK, Lee CK, Liang R, Chim JC, **Leung AY** and Kwong YL. ICE Chemotherapy Plus peripheral Blood Stem Cell (PBSC) Rescue for relapse after bone marrow transplantation (BMT), The 4th Joint Shanghai-Hong Kong Haematology Meeting. 2000.

65. **Leung AY**, Suen CK, Lie AK, Liang R, Yuen KY and Kwong YL. A Study of the role of polyoma virus in Haemorrhagic cystitis in bone marrow transplantation patients, The 4th Joint Shanghai-Hong Kong Haematology Meeting. 2000.

66. **Leung AY**, Chow CH, Fung TK, Chow WH, Yip AS and Liang R. A study of the cytochrome P450 2C9 Genotypes in Chinese patients receiving warfarin - a phenotypic correlation, The 4th Joint Shanghai-Hong Kong Haematology Meeting. 2000.

67. **Leung AY**, Chow CH, Kwong YL, Lie AK, Fung TK, Chow WH, Yip AS and Liang R. Genetic polymorphism at exon 4 of cytochrome P450CYP2C9 in Chinese patients might determine the warfarin dose requirement., 42nd Annual Meeting of the American Society of Hematology. San Francisco.. 2000.

68. **Leung AY**, Chim JC, Kwong YL, Lie AK, Au WY and Liang R. Retrospective studies of 230 Chinese adults with chronic idiopathic thrombocytopenia purpura., The Hong Kong Society of Haematology Annual Open Scientific Meeting & The 4th Joint Shanghai-Hong Kong Haematology Meeting 2000.

69. **Leung AY**, Chen FE, Chen P, Lie AK, Hawkins BR, Lau G and Liang R. The use of cytotoxic T-lymphocyte precursor (CTL) and helper T-lymphocyte precursor (HTLP) frequencies in the prediction of occurrence and severity of graft-versus-host disease after bone marrow transplantation, The 4th Joint Shanghai-Hong Kong Haematology Meeting. 2000.

70. Liang R, Lee CK, Lie AK, **Leung AY**, Kwong YL, Chim JC, Au WY, Lau YL, Lim WL and Lau G. A case-controlled study on the use of HbsAg positive donors for allogeneic bone marrow transplantation., 36th Annual Meeting of the American Society of Clinical Oncology. 2000.

71. Lie AK, **Leung AY** and Liang R. A Comparison of Non-TBI and TBI-containing preparatory regimes in bone marrow recipients undergoing matched-unrelated transplantation, The 4th Joint Shanghai-Hong Kong Haematology Meeting. 2000.

72. Lie AK, **Leung AY** and Liang R. A Comparison of treatment outcomes of bone marrow transplantation from HLA-identical siblings, one HLA-Antigen mismatched siblings and matched unrelated donors, The 4th Joint Shanghai-Hong Kong Haematology Meeting. 2000.

73. Lie AK, **Leung AY** and Liang R. A comparison of non-TBI and TBI conditioning regimens in bone marrow recipients undergoing match-unrelated transplantation in Hong Kong., IBMTR/ABMTR Tandem BMT Meetings 2000. 12: A27.

74. Lie AK, **Leung AY** and Liang R. A comparison of non-TBI and TBI containing preparatory regimens in bone marrow recipients undergoing match-unrelated transplantation., The Hong Kong Society of Haematology Annual Open Scientific Meeting & The 4th Joint Shanghai-Hong Kong Haematology Meeting 2000. 22.

75. Lie AK, **Leung AY** and Liang R. A comparison of treatment outcomes of bone marrow transplantation from HLA-identical siblings, one HLA antigen Mismatched siblings and matched unrelated donors., The Hong Kong Society of Haematology Annual Open Scientific Meeting & The 4th Joint Shanghai-Hong Kong Haematology Meeting 2000. 23.

76. Lie AK, Au WY, Siu LL, Liang R, **Leung AY** and Kwong YL. Intensive chemotherapy with peripheral blood stem cell support for leukaemia relapse after allogeneic bone marrow transplantation. 7th Asian Pacific BMT group meeting, Bangkok.. 2000, 130-131.

77. **Leung AY** and Wong PY. Effects of adrenergic agonists on transepithelial chloride secretion and Ca^{2+} in cultured cauda epididymal cells of rats, Proceedings of the Physiological Society, Dundee Meeting, 1992.

78. **Leung AY** and Wong PY. Studies of thapsigargin on Ca²⁺ in cultured cauda epididymal cells of rats, Proceedings of the Physiological Society, Dundee Meeting, 1992.
79. **Leung AY** and Wong PY. Human epididymal cells respond to adrenaline by increase in short-circuit current and whole-cell chloride current, Proceedings of the Physiological Society, St Andrews Meeting, 1992.
80. **Leung AY** and Wong PY. A method for studying apical anion conductance in cultured rat epididymal cells using the short-circuit current technique, Proceedings of the Physiological Society, St Andrews Meeting, 1992.

Local Conference Papers

81. He BL, **Leung AY**. Modeling FLT3-ITD Acute Myeloid Leukemia in Zebrafish to Identify Follistatin as a Promising Therapeutic Target for Translational Medicine. 22nd Medical Research Conference, 2017. Department of Medicine, The University of Hong Kong.
82. Lam SS, Cher CY, Ng KL, Man, Ho ES, Chow HC, Cheung AM, **Leung AY**. Development of a clinically relevant in vitro drug screening platform for chemo-refractory AML patients. 20th Medical research conference, Hong Kong. January, 2015.
83. Lam SS, Man CH, Chow HC, Cheung AM, **Leung AY**. Small molecule inhibitors screening platform for optimized design of personalized treatment for chemo- refractory acute myeloid leukaemia patients. 19th Hong Kong International Cancer Congress, Hong Kong, 2012.
84. Man CH, Sun MK, Chow HC, Cheung AM and **Leung AY**. Treatment of amiloride is effective in killing sorafenib-resistant AML cells. 19th Hong Kong International Cancer Congress, Hong Kong 2012.
85. Man CH, Fung TK, Ho CM, Han HH, Chow HC, Ma AC, Choi WW, Kwong YL and **Leung AY**. Effect of Sorafenib treatment in FLT3-ITD+ acute myeloid leukemia: Mechanism of non-responsive and emergence of novel clones, 18th Hong Kong International Congress, 2011.
86. Han HH, Man CH, Fung TK, Ma AC, Chow HC and **Leung AY**. Targeting JAK/STAT pathway in acute myeloid leukemia (AML) – A potential therapeutic strategy and its link to WNT pathway, 18th Hong Kong International Congress, 2011.
87. Fung TK, Liang R and **Leung AY**. Functional characterization of novel gene NUP98 in zebrafish embryo, 15th Medical Research Conference, 2010.
88. Ma AC, Lin H, Chung IS, Yang D, Liang R and **Leung AY**. Distinctive functions of methionine aminopeptidase II in embryonic hematopoiesis in zebrafish embryos. 15th Medical Research Conference. Hong Kong, 2010.
89. Ma CH, Liang R and **Leung AY**. The effect of Diethylaminobenzaldehyde (DEAB), an inhibitor of Aldehyde Dehydrogenase (Aldh), on Primitive Hematopoiesis during Zebrafish Embryonic Development, 16th Hong Kong International Cancer Congress. 2009.
90. Ma AC, Ward AC, Lewis RS, Liang R, **Leung AY**. The study of Jak2 V617F mutation in polycythemia vera with zebrafish model. 14th Medical Research Conference, Hong Kong, 2009.
91. Fung TK and **Leung AY**. Functional characterization of novel gene NUP98 in zebrafish embryo, 16th Hong Kong International Cancer Congress 6th Annual Meeting Centre for Cancer Research, 2009.
92. Chan CF, **Leung AY**, Chan YS and Cheung RT. Use of granulocyte-colony stimulating factor in a mice stroke model, 11th Research Postgraduate Symposium. 2006.
93. Ma AC, Liang R and **Leung AY**. The role of survivin-2 in primitive hematopoiesis during zebrafish embryonic development. The 13th Hong Kong International Cancer Congress, 2006.
94. Kwan TT, Cheng CL, Liang R and **Leung AY**. Function of survivin during embryonic angiogenesis and hematopoiesis in a zebrafish model, 1st Annual Conference of the OOTR, Hong Kong, 2004.
95. Au WY, Chan GC, Chim JC, Liang R, Lie AK, **Leung AY** and Kwong YL. Sustained and

repeated response of relapsed acute promyelocytic leukemia (APL) to arsenic therapy. *The Hong Kong Practitioner*. 2001, 23(Suppl): 49.

96. Au WY, Lie AK, Siu LL, Liang R, Chim JC, **Leung AY** and Kwong YL. Intensive chemotherapy with peripheral blood stem cell (PBSC) support in the treatment of leukemic relapse after allogeneic bone marrow transplantation, 6th Medical Research Conference, Hong Kong, 2001.

97. **Leung AY**, Lie AK, Kwong YL, Yuen KY, Au WY, Wong KK, Kwok JS, Lee TL, Cheng VC and Liang R. The 23-valent polysaccharide pneumococcal vaccination is not useful in BMT patients at risk of pneumococcal bacteremic sepsis, 6th Medical Research Conference, Hong Kong, 2001.

98. **Leung AY**, Yuen KY, Cheng VC, Lie AK, Liang R. and Kwong YL. Clinical characteristics and risk factors of herpes zoster after bone marrow transplantation, 6th Medical Research Conference, Hong Kong, 2001.

99. **Leung AY**, Chen FE, Lie AK, Chen P, Kwok JS and Liang R. Helper T-lymphocyte precursor frequency (HTLPf) predicts the occurrence of graft-versus-host disease (GVHD) after allogeneic bone marrow transplant., 6th Medical Research Conference, Hong Kong, 2001.

100. Lie AK, **Leung AY**, Au WY, Hawkins BR and Liang R. Unmanipulated bone marrow transplantation from one HLA antigen mismatched siblings carries high transplant-related mortality compared with the HLA-identical counterparts., 6th Medical Research Conference, Hong Kong, 2001.

101. Au WY, Lie AK, Lee CK, Liang R, Chim J, **Leung AY**, and Kwong YL. ICE/BEAM chemotherapy plus peripheral blood stem cell (PBSC) rescue for relapse after bone marrow transplantation (BMT), The 5th Medical Research Conference. 2000.

102. **Leung AY**, Yuen KY, Lie AK, Kwong YL and Liang R. Herpes zoster virus infection after bone marrow transplantation. 7th Hong Kong International Cancer Congress. 2000.

103. **Leung AY**, Lie AK, Liang R, Yuen KY, Suen CK and Kwong YL. A Study of the role of polyoma virus in Haemorrhagic cystitis in bone marrow transplantation patients, The 5th Medical Research Conference, Hong Kong, 2000.

104. **Leung AY**, Lie AK, Kwong YL, Yuen KY, Au WY, Wong KK, Kwok JS, Lee TL, Cheng VC and Liang R. The 23-valent polysaccharide pneumococcal vaccination is not useful in BMT patients at risk of pneumococcal bacteremic sepsis. 7th Hong Kong International Cancer Congress, 2000.

105. Lie AK, **Leung AY** and Liang R. Non-TBI conditioning regimens were associated with less transplant-related morbidity and mortality in patients who received BMT from matched-unrelated donors. 7th Hong Kong International Cancer Congress, 2000.

106. Lie AK, **Leung AY**, Au WY, Hawkins BR and Liang R. Unmanipulated bone marrow transplantation from one HLA antigen mismatched siblings carries high transplant-related mortality compared with the HLA-identical counterparts. 7th Hong Kong International Cancer Congress, 2000.

107. Lee CK, Lie AK, Au WY, **Leung AY**, Chim JC, Kwong YL and Liang R. Bone Marrow Transplantation in Chinese patients with multiple myeloma, 6th Hong Kong International Cancer Congress, 1999.

108. Lee CK, Lie AK, **Leung AY**, Au WY, Chim JC, Kwong YL and Liang R. Incidence of acute graft-versus-host disease after allogeneic bone marrow transplantation in adult Chinese patients, 6th Hong Kong International Cancer Congress, 1999.

ESTEEM MEASURES AND INTERNATIONAL PRESTIGE

Research Awards

1. Outstanding Research Student Supervisor Award (2018), University of Hong Kong
2. Faculty Outstanding Research Output Prize 2017
Paper: Homoharringtonine (omacetaxine mesopropylsuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. *Sci Transl Med* 2016; 8(359):359ra129.
2. Li Shu Fan Medical Foundation Endowed Professorship in Haematology (Since 2014)
Project Title: Haematopoiesis and leukaemia
Award Amount: Perpetual income from a permanent endowment of HKD 20 millions
3. Croucher Senior Medical Research Fellowships (2016)
Project Title: Develop a high throughput platform for personalized treatment of acute myeloid leukaemia
Award Amount: HKD 4,288,400
Duration: 12 months

Honorary academic positions

1. Visiting Professor of Shanghai Jiao Tong University Medical School (2011-2014)
2. Honorary Professor, Peking Union Medical College (Since 2017)

Participation in international organizations (* Important contribution)

1. Medical Research Council
Ad hoc international reviewer for fellowships application (Since 2011-)
2. Leukaemia & Lymphoma Research
Ad hoc international reviewer for grant application (Since 2012-)
3. Faculty of F1000
Duties: As member to review and write commentaries on publications in areas of hematopoiesis and hematopoietic stem cell transplantation (2012-2016).
4. Royal College of Physicians (UK)*
Haematology specialist in Part I Board of MRCP (UK) (Since 2013-)
Duties: Quality assurance of examination questions (haematology) for MRCP (Part I) in UK and other overseas centres.
5. Austrian Academy of Sciences
Ad hoc international reviewer to select doctoral fellowship (Since 2014-)
6. European Molecular Biology Organization (EMBO)*
Chief organizer, EMBO Workshop in Stem Cells and Epigenetics in Cancers (2014)
7. East West Alliance Meeting
Co-chair, EWA meeting at HKU (2014)
8. University Sains Malaysia, Penang, Malaysia
External Assessor to select Professor for Haematology (Since 2015-)
9. Barts Charity, UK
Ad hoc international reviewer to select clinical fellowship (Since 2017-)
10. Blood Cancer UK (formally known as Bloodwise)
Ad hoc expert reviewer to review grant proposal (Since 2020-)
11. Czech Science Foundation (the main public funding agency in the Czech Republic supporting all areas of basic research)
Ad hoc reviewer of grant proposal (Since 2020-)

Reviewers of international peer reviewed journals

1. Experimental Hematology
2. Gene Expression Pattern
3. Bone Marrow Transplantation
4. Medical Principles and Practice
5. PLoS ONE
6. BioTechniques
7. British Journal of Cancer
8. BLOOD
9. Clinical Interventions in Aging
10. Developmental Biology
11. Molecular Biology Reports
12. Zebrafish
13. Stem Cells
14. Experimental Biology and Medicine
15. PNAS
16. Comparative Biochemistry and Physiology
17. Haematologica- The Haematology Journal
18. Journal of Obstetrics and Gynaecology Research
19. FASEB J
20. Current Cancer Drug Targets
21. Acta Haematologica
22. Clinica Chimica Acta
23. Stem Cells and Development
24. International Journal of Developmental Biology
25. Development
26. Development Genes and Evolution
27. Oncotarget
28. Science Translational Medicine

International Advisory Board Memberships (Since 2012)

Role: Advise on biology, epidemiology and treatment paradigm of myeloid neoplasms and present original data from Hong Kong in regional and international advisory boards. Specific examples include:

- 2012: Steering Committee of Peripheral Blood Stem Cell Mobilization, Sanofi.
- 2014-16: Asian AML and MDS Advisory Board, Boehringer Ingelheim
- 2016: Celgene Clinical Research and Development in MDS & AML
- 2017: Regional AML Advisory Board, Celgene.
- 2017-18: Regional AML Advisory Board, Novartis.
- 2018- Research Advisor, Nan Yang Academy of Sciences (Singapore)

Participation in international clinical trials (as PI in Hong Kong) (Since 2012)

1. A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation.
2. A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia.
3. A phase II, randomized, double-blind, multi-center, placebo-controlled study in Asia and Russia to evaluate the efficacy and safety of twice daily oral midostaurin in combination with daunorubicin/cytarabine induction, high-dose cytarabine consolidation, and midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML)
4. A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine versus venetoclax plus azacitidine in previously untreated patients with TP53 mutant acute myeloid leukemia who are ineligible for intensive induction chemotherapy.

5. A randomized, double-blind multicenter study comparing magrolimab in combination with azacitidine versus azacitidine plus placebo in treatment-naïve patients with higher risk myelodysplastic syndrome.
6. Phase 2 open-label, multicenter, dose optimization clinical study of the safety, tolerability, and pharmacokinetic and pharmacodynamics profiles of CFI-400945 as single agent or in combination with azacitidine or decitabine in patients with acute myeloid leukemia.

Active investigator-initiated studies (as PI) (Since 2012)

1. A Phase II study on the use decitabine (10 days regimen) for the treatment of complex and/or monosomal AML in adults.
Funding support: HKD 831,597.86
First recruitment: October 2016
2. A Phase II single-arm open-labeled study evaluating combination of quizartinib and omacetaxine mepesuccinate (QUIZOM) in newly diagnosed or relapsed/refractory AML carrying FIT3-ITD
Funding support: HKD 2,140,155.09
First recruitment: October 2017

Important Editorial board membership by invitation:

1. Blood (Impact Factor 17.543) Since January 2018- (Blood is the official journal of the American Society of Hematology with the highest impact factor in haematology. I am among the few members from Asian region in the Board)
2. Guest editorship of Frontiers in Cell and Development Biology (Impact Factor: 5.201, Rank: 6/41 in developmental biology) (Since 2020-)

Invited lectures by overseas institutions or international/national conferences

1. National Haematology Expert Meeting
Title: Emerging targeted therapies in FLT3 mutated AML
Venue: Kuala Lumpur, Malaysia
Year: 2018
 2. The Asia Pacific Summit of Haematology in Taiwan
Title: Treatment of acute myeloid leukemia in the next decade – full panel genetic profiling and personalized medicine
Venue: Taipei
Year: 2018
 3. *The 6th Thai Society of Hematology – International Symposium
Title: Targeting novel signaling pathway for AML (Plenary Talk)
Venue: Bangkok
Year: 2018
- * An international symposium in which I was invited to give 2 plenary talks on AML (http://tsh.or.th/tsh-is/assets/files/Sci_ProgramMyeloidDisorders_updated03-12.pdf)**
4. Myeloid Preceptorship Program
Title: Molecular abnormalities in acute myeloid leukemia
Venue: Seoul
Year: 2017
 5. Johns Hopkins University
Title: Targeted therapy for human acute myeloid leukemia.

Venue: Cancer Research Building 1, Johns Hopkins University, Baltimore
Year: 2016

6. University of Toronto

Title: Targeted therapy for human AML: From zebrafish to human leukemia
Venue: Princess Margaret Hospital, University of Toronto, Toronto
Year: 2016

7. *3rd Chinese Zebrafish PI Meeting

Title: Novel role of Arl4aa in definitive haematopoiesis
Venue: Wuhan
Year: 2016

*** A nation-wide conference with all top-notch Chinese zebrafish researchers participating. I was selected and invited to present in the plenary session.**

8. QuANTUM-R Investigator Meeting in Taiwan

Title: Special lecture- Recent research for AML: Novel biomarker and novel therapeutic agents
Venue: Taipei
Year: 2016

9. Macau Society of Hematology and Oncology

Title: How do I treat elderly AML
Venue: Macau
Year: 2015

10. *EMBO Workshop in Stem Cells and Epigenetics in Cancers

Title: Personalized treatment for AML – are we there yet?
Venue: Hong Kong
Year: 2014

*** A prestigious meeting with top-notch international scientists and clinicians in haematology and medical oncology. I was invited to present in one of the keynote sessions.**

11. CML Speaker Tour in Korea

Title: How to choose optimal TKI for CML treatment
Venue: Busan and Seoul, Korea
Year: 2014

12. Cross Strait Transplantation Forum

Title: BKV reactivation in hematopoietic stem cell transplantation
Venue: Nanjing
Year: 2014

13. 6th Asia Oceania Zebrafish Meeting

Title: Modeling human FLT3-ITD AML with zebrafish model
Venue: Hong Kong
Year: 2014

14. First Taiwan, Japan, Hong Kong CML Joint Meeting

Title: Understanding the treatment response and epidemiological burden of CML patients
Venue: Sapporo
Year: 2013

15. Asia Pacific Hematology Forum

Title: Poor mobilizer/re-mobilizer undergoing autologous HSCT
Venue: Beijing
Year: 2013

16. *11th Round Asia Oncology Forum

Title: Novel therapeutics in the treatment of leukemia

Venue: Taipei, Taiwan

Year: 2012

*** A regional conference with large number of audience and I was invited as keynote speaker in one of the sessions.**

17. Macau Society of Nephrology

Title: Quantitative analysis of BK virus in transplant recipients

Venue: Hotel Royal, Macau

Year: 2012

18. Shanghai Jiao Tong University, School of Medicine

Title: Targeted therapy in acute myeloid leukemia

Venue: Renji Hospital, Shanghai, China

Year: 2011

19. Second Chinese Blood and Marrow Transplantation Forum

Title: Bridging to Bone Marrow Transplantation: The Use of Targeted Therapy for Salvage Treatment for Patients with AML

Venue: Guilin, China

Year: 2011

20. Karolinska Institute - Hong Kong Regenerative Medicine Workshop

Title: Hematopoietic stem cells and acute myeloid leukemia

Venue: Stockholm, Sweden

Year: 2011

21. National Health Research Institutes Symposium

Title: When hematopoiesis goes awry-a study of human leukemia based on zebrafish model

Venue: Taiwan

Year: 2011

22. Deakin School of Medicine, Geelong, Victoria, Australia

Title: Hematopoietic stem cell regulation and development - the lesson we learn from zebrafish and leukemia with reference to aldehyde dehydrogenase

Venue: Victoria, Australia

Year: 2010

23. Hong Kong-Beijing-Xian Medical Forum

Title: Interesting cases in Haematology

Venue: Xian, China

Year: 2010

24. Approaches in the treatment of haematological malignancies - Asia Pacific Forum

Title: Treatment of autoimmune cytopenia by Alemtuzumab

Venue: Sydney, Australia

Year: 2006

25. Joint seminar of the Centre of Developmental Biology -The University of Hong Kong.

Title: The use of zebrafish as a model for the study of primitive hematopoiesis during embryonic development.

Venue: Kobe, Japan

Year: 2005

26. Roche Asian Transplantation and Immunology Forum.

Title: Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm.

Venue: Jeju, Korea

Year: 2005

Invited lectures and keynote speech at local conferences

1. Meeting: Hong Kong Society of Haematology Scientific Meeting
Title: AML treatment in Hong Kong (23 My 2018)
2. Meeting: Hospital Authority Convention
Title: Personalized treatment for acute myeloid leukaemia (7 May 2018)
3. Meeting: 6th Hong Kong Pathology Forum
Title: Significance of genomics in the management of acute myeloid leukaemia (3 February 2018)
4. Meeting: Guest Lecture in Department of Biomedical Sciences, CityUHK
Title: Targeted therapy for acute myeloid leukemia (2 September 2016)
5. Meeting: Guest Lecture in Medical Engineering Programme, Faculty of Engineering. HKU
Title: Stem Cell Research and Application (21 April, 2016)
6. Meeting: Annual Scientific Meeting of CRDG 2015, LKS Faculty of Medicine
Title: Identification of novel targets and biomarkers of acute myeloid leukemia based on the zebrafish model
7. Meeting: 21st Hong Kong Medical Forum 2015
Title: Advances in the treatment of myeloid malignancies in two decades.
8. Meeting: 2014 International Conference on advanced molecular technologies
Title: Personalized medicine for acute myeloid leukemia, are we there yet?
9. Meeting: Hong Kong Pathology Forum 2014
Title: Medical Treatment of Leukemia
10. Meeting: 20th Hong Kong International Cancer Congress (2013)
Title: Personalized medicine in acute myeloid leukemia
11. Meeting: 1st Annual Scientific Meeting of the Hong Kong for Histocompatibility and Immunogenetics.
Title: From haematopoietic stem cells to human acute myeloid leukemia (2013)
12. Meeting: Multi-specialty Medical Mega Conference 3rd Round (2013)
Title: Stem cell therapy in Haematology
13. Meeting: 18th Annual Scientific Conference of the Hong Kong Society of Transplantation
Title: An overview of stem cells – are they ready for the clinics?
14. Meeting: 20th Annual Scientific Meeting of the Hong Kong College of Radiologists (2012)
Title: Management of elderly patients with lymphoma – QMH experience
15. Meeting: Multi-specialty medical mega conference (2012)
Title: Molecular mechanisms and successful target therapies in hematological disease.
16. Meeting: Frontiers in Biomedical Research, HKU (2011)
Title: Stem cell and acute myeloid leukemia
17. Meeting: BKV symposium, Hong Kong Society of Transplantation (2011)
Title: Beyond quantification of BK virus in organ transplantation.
18. Meeting: Annual Scientific Meeting, Hong Kong Society of Transplantation (2011)
Title: Outcome of HSCT for haematological cancers
19. Meeting: Annual Scientific Meeting, Hong Kong College of Physicians (2011)
Title: Novel treatments for myeloid malignancies
20. Meeting: Forum on haematological Malignancies (2011)
Title: The current and novel therapies for myeloproliferative neoplasms
21. Meeting: Monthly Scientific Meeting, Hong Kong Society of Haematology (2011)
Title: Targeted therapy in acute myeloid leukemia
22. Meeting: The Second Asia Pacific Symposium on Advanced Molecular Technologies (2010)
Title: Keynote Speech: New therapeutic options in acute myeloid leukemia

23. Meeting: Annual Scientific Meeting, Hong Kong Society of Transplantation (2010)
Title: Graft versus host disease- an update on prevention and management
24. Meeting: Hong Kong International Cancer Congress (2008)
Title: Recent advances in chronic myeloproliferative diseases
25. Meeting: Hong Kong International Cancer Congress (2008)
Title: The search in stemness in acute myeloid leukemia
26. Meeting: Departmental Seminar, Department of Chemical Pathology, CUHK (2008)
Title: What I learn from zebrafish in hematopoiesis and blood cancers
27. Meeting: Hong Kong International Cancer Congress (2007)
Title: Zebrafish model of human blood cancers
28. Meeting: Stem Cell Workshop, Strategic Research Theme of Development and Reproduction (2006)
Title: The role of survivin in hematopoiesis and angiogenesis during zebrafish development
29. Meeting: Annual Scientific Meeting, Hong Kong Society of Transplantation (2006)
Title: A novel approach for the prevention of herpes zoster during hematopoietic stem cell transplantation using adoptive transfer of immunity
30. Meeting: International symposium on healthy aging (2006)
Title: Zebrafish as a model of hematopoietic regeneration
31. Meeting: Hong Kong International Cancer Congress (2005)
Title: Hematopoietic stem cell transplantation: From laboratory to the clinics
32. Meeting: The Croucher Foundation Advanced Study Institute on Stem Cell Research (2005)
Title: Using zebrafish as a model for the study of hematopoietic stem cell during embryonic development
33. Meeting: Hong Kong Medical Forum (2005)
Title: Viral reactivation after hematopoietic stem cell transplantation – the BKV paradigm.
34. Meeting: Annual Scientific Meeting, Hong Kong Society of Transplantation (2004)
Title: Ciprofloxacin reduces BKV viruria in bone marrow transplantation
35. Meeting: Departmental Seminar, Department of Anatomy, HKU (2004)
Title: Assigning molecular signatures to dorsoventral patterning in a zebrafish model - with special reference to early embryonic hematopoietic development.
36. Meeting: Departmental Seminar, Department of Biochemistry, HKU (2004)
Title: Hematopoietic stem cell cell-fate decision: Lesson from zebrafish.
37. Meeting: Monthly Scientific Meeting, Hong Kong Society of Haematology (2003)
Title: Role of Bone Morphogenetic Proteins and their antagonists in hematopoiesis – from embryonic development to hematopoietic stem cell ex-vivo expansion.
38. Meeting: Joint Scientific Meeting, Hong Kong College of Physicians (2003)
Title: Characterization of expanded hematopoietic cells in the intermediate cell mass of the chordin morphants generated by anti-sense morpholino.
39. Meeting: Joint Scientific Meeting, Hong Kong College of Physicians (2002)
Title: Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation

Memberships in International Organization

1. International Society for Stem Cell Research
2. International Society of Experimental Hematology
3. American Society of Hematology

SUCCESS IN MENTORING / TRAINING NEXT-GENERATION LEADERS

Award Winning Research Postgraduate Students (As Principal Supervisor)

* PhD students with outstanding score (top 5%) in thesis examinations.

**One representative publication arising from thesis was listed.

1. **Cheung Man-Sze Alice (PhD 2005-2008)***

Awards:

1. Outstanding Research Postgraduate Student Award (HKU) for the year 2007-2008;
2. Croucher Foundation Research Studentship/Buttlefield-Croucher Studentship 2007.

Representative publication**:

Cheung AM...Leung AY. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential.

Impact Factor: 8.665; **Rank:** 5/76 in Hematology; **Citation:** 174.

First job after PhD graduation: Postdoctoral Fellow, Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada.

Current job: Scientist, Cancer and Stem Cell Biology, Duke-NUS, Singapore.

2. **Man Cheuk Him (2010-2013)***

Awards:

1. Poster prize, Hong Kong International Cancer Congress 2011;
2. Young Scientist Award 2014 (Honorable Mention in Life Science), Hong Kong Institute of Science.

Representative publication**:

Man CH...Leung AY. Sorafenib treatment of FLT3-ITD + acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. *Blood* 2012;119(22):5133-43. **Impact Factor:** 17.543; **Rank:** 1/76 in Hematology;

Citation: 170.

After PhD graduation: Postdoctoral Fellow, Dr. David Scadden's Laboratory, Harvard Stem Cell Institute, USA

Current job: Research Assistant Professor, Department of Medicine, LKS Faculty of Medicine, University of Hong Kong.

3. **Wong Sean Man Natalie (MResMed 2011-2012)**

Awards:

1. Conference Grant to ISSCR (2010);
2. Hou De Charitable Foundation Scholarship.

Current Job: Resident specialist in Clinical Oncology, Hospital Authority, HK.

4. **Ng Koo Kiu (MResMed 2012-2013)**

Awards:

1. Yu Chun Keung Memorial Scholarships;
2. Mr & Mrs SH Wong Foundation Scholarship;
3. Hou De Charitable Foundation Scholarship.

Current Job: Resident specialist in Diagnostic Radiology, Hospital Authority, HK.

5. **Shi Xiangguo (PhD 2012-2015)***

Awards:

1. HKU University Postgraduate Fellowship (UPF)

Representative publication**:

Shi X...Leung AY. Functions of *idh1* and its mutation in the regulation of developmental hematopoiesis in zebrafish. *Blood*. 2015; 125(19): 2974-84. **Impact Factor:** 17.543; **Rank:** 1/76 in Hematology; **Citation:**11

First job after PhD graduation: Postdoctoral Fellow, Dr. Daniel Tenen's Laboratory, National University of Singapore, Singapore.

6. **He Bailiang Alex (PhD 2012-2015)***

Awards:

1. Li Ka Shing Prize 2017 (**One of the best PhD theses in the University of Hong Kong**)
2. Dr. KP Stephen Chang Gold Medal (2015-2016) (**Best PhD Thesis in the Faculty**)
3. Yu To Sang and Yu Shing Keung Memorial Fund Scholarship 2014/15;
4. Best oral presentation award in 22nd Medical Research Conference, Department of Medicine, 2017;

Representative publication**:

He BL...Leung AY. Functions of *flt3* in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. *Blood*. 2014;123(16):2518-29. **Impact Factor:** 17.543; **Rank:** 1/76 in Hematology; **Citation:** 27.

First job after PhD graduation: Postdoctoral Fellow, Department of Medicine, LKS Faculty of Medicine, University of Hong Kong.

Current job: Associate Professor, Sun Yat-Sen University, Guangzhou, China

7. **Lam Sze Yuen Stephen (PhD 2013-2016)***

Awards:

1. Outstanding Research Postgraduate Student Award (HKU) for the year 2017
2. Croucher Foundation Fellowships;
3. Abstract achievement award – 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA Dec 2014;
4. Best poster presentation award – 17th Research Postgraduate Symposium, Faculty of Medicine, the University of Hong Kong Dec 2012

Representative publication**:

Lam SY...Leung AY. Homoharringtonine (omacetaxine mepessucinate) as an adjunct for FLT3-ITD acute myeloid leukemia. *Sci Transl Med* 2016; 8(359):359ra129. **Impact Factor:** 16.304; **Rank** 2/138 in Medicine: Research & Experimental; **Citation:** 26.

Current job: Resident trainee, Hospital Authority, Hong Kong

8. **Cher Chae Yin (PhD 2014-)**

Awards:

1. HK PhD Fellowship
2. Wong Ching Yee Medical Postgraduate Scholarships & YS and Christabel Lung Postgraduate Scholarship 1026/17

Representative publication**:

Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, Leung AY. Next-generation sequencing with a myeloid gene panel in core-binding

factor AML showed KIT activation loop and TET2 mutations predictive of outcome. Blood Cancer J. 2016; 6(7): e442.

Impact Factor: 8.023; **Rank:** 25/244 in Oncology; **Citation:** 18.

First job after PhD graduation: Research Scientist II, Lucence, Singapore.

9. Cheng Yik Ling Bowie (PhD 2016-2019)

Awards: Croucher Foundation Research Studentships (2017/18) and Butterfield Croucher Studentship (2017/18)

Representative publication*

Guo Y, Cheng BYL*, Wang D, Ma ACH, He BL, Man TK, Cheung MPL, Shi X, Ng NKL, Leung AYH. Function of Arl4aa in the Initiation of Hematopoiesis in Zebrafish by Maintaining Golgi Complex Integrity in Hemogenic Endothelium. Stem Cell Reports. 2020;14(4):575-589.

Impact Factor: 6.032; **Rank** 5/29 in Cell & Tissue Engineering; **Citation:** N.A.

First job after PhD graduation: Post-doctoral fellow, Dr. Taia T Wang's Lab, Stanford University, US.

10. Ng Ka Lam (PhD 2015-2018)

AWARD: HKU/KCL JOINT PH.D. FELLOWSHIP

Representative publication**

Leung GM*, Zhang C*, Ng NK*, Yang N, Lam SS, Au CH, Chan TL, Ma ES, Tsui SP, Ip HW, So CC, Ng MH, Cheng KC, Wong KF, Siu LL, Yip SF, Lin SY, Lau JS, Luk TH, Lee HK, Lau CK, Kho B, Kwong YL, Leung AY. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations. Am J Hematol. 2019; 94(6): 650-657. * Co-first authorship.

Impact Factor: 6.973; **Rank** 8/76 in Haematology; **Citation:** 12.

First job after PhD graduation: Post-doctoral fellow, LKS Faculty of Medicine, University of Hong Kong.

Graduate students under my principal supervision

1.	Kwan Tin Fu.	MPhil.	Year of graduation: 2005
2.	Wong Seung Yee, Anders.	MPhil.	Year of graduation: 2006
3.	Cheung Man Sze, Alice.	PhD,	Year of graduation: 2008
4.	Ma Chun Hang, Alvin.	PhD.	Year of graduation: 2008
5.	Lui Ka Luen.	MMed Sc.	Year of graduation: 2008
6.	Lo Carfield, Cathy.	MPhil.	Year of graduation: 2008
7.	Lin Huichao.	MPhil.	Year of graduation: 2009
8.	Fan Kin Pong.	MPhil.	Year of graduation: 2010
9.	Chung In Shing.	PhD.	Year of graduation: 2010
10.	Wong Sean Man Natalie.	MResMed.	Year of graduation: 2011
11.	Tsui Chi On.	MBiomedSc.	Year of graduation: 2011
12.	Man Hon Wai, Johnny.	MMedSc.	Year of graduation: 2012

13.	Han Ho Chung.	MPhil.	Year of graduation: 2012
14.	Wan Haixia.	PhD.	Year of graduation: 2012
15.	Ng Koo Kiu,	MResMed.	Year of graduation: 2012
16.	Man Cheuk Him.	PhD.	Year of graduation: 2013
17.	Shi Xiangguo.	PhD.	Year of graduation: 2015
18.	He Bailiang Alex.	PhD.	Year of graduation: 2015
19.	Ho Siu Ki Eric.	PhD.	Year of graduation: 2015
20.	Ho Mun Yung.	PhD.	Year of graduation: 2016
21.	Lam Sze Yuen Stephen.	PhD.	Year of graduation: 2016
22.	Guo Yu Han.	PhD.	Year of graduation: 2016
23.	Chan Kwok Hei.	MResMed.	Year of graduation: 2017
24.	Cher Chae Yin	Ph.D.	Year of graduation: 2018
25.	Ng K.L. Nelson	Ph.D.	Year of graduation: 2018
26.	Cheng Yik Ling Bowie	Ph.D.	Year of graduation: 2019
27.	Kan Lai Hok Leo	M.Phil.	Year of graduation: 2019

Current graduate students under my principal supervision

1. Wang Dang Dang Ph.D. Candidate
2. Dang Chee Chean Kenny Ph.D. Candidate

Current postdoctoral fellows under my principal supervision

1. Dr. Nelson K.L. Ng Since 2017-
2. Dr. Ning Yang Since 2017-

Current research assistant professor under my principal supervision

1. Dr. Cheuk Him Man Since 2019 –
2. Dr. Sally Sun Since 2019 -

Previous postdoctoral fellows under my principal supervision

1. Dr. Alvin C.H. Ma (2010-2013)
Current position: Assistant Professor, Hong Kong Polytechnic University.
2. Dr. Tsz-Kan Fung (2010-2013)
Current position: Postdoctoral Fellow, Professor Eric So's Laboratory, King's College London
3. Dr. Cheuk-Him Man (2014-2016)
Current position: Research Assistant Professor, LKS Faculty of Medicine, University of Hong Kong.
4. Dr. Henry Wong (2017)
5. Dr. Li Laam (2017)
6. Dr. Bailiang He 2015-2018
Current position: Associate Professor, Sun Yat-Sen University, Guangzhou, China

Previous research assistant professor under my principal supervision

1. Dr. Alvin C.H. Ma (2013-2016)
Current position: Assistant Professor, Hong Kong Polytechnic University.
2. Dr. Alice M.S. Cheung (2012-2014)
Current position: Scientist, Cancer and Stem Cell Biology, Duke-NUS, Singapore.

External examiner for graduate students

Date	Institution	Students	Degree	Role
2006	Institute of Chinese Medical Sciences, University of Macau	Lam Hio Wa	M.Sc.	External Examiner
2007	Institute of Chinese Medical Sciences, University of Macau	Lin Hui Chao	M.Sc.	Chairperson, Oral Defence Committee
2007	City University of Hong Kong School of Life and Environmental Sciences, Deakin University, Australia	Chen Xueping	Ph.D.	External Examiner
2009	School of Life and Environmental Sciences, Deakin University, Australia	Ms Lynda O'Sullivan	Ph.D.	External Examiner
2009	School of Life and Environmental Sciences, Deakin University, Australia	Mr. Clifford Liongue	Ph.D.	External Examiner
2011	Department of Biochemistry, HKUST	Mr. Li LI	Ph.D.	External Examiner
2012	Department of Biochemistry, CUHK	Shi, Yujian	Ph.D.	External Examiner
2013	Institute of Chinese Medical Sciences, University of Macau	Guo Zhen Cui	Ph.D.	External Examiner
2015	Department of Anatomical and Cellular Pathology. CUHK	Wong Hei Yan Henry	M.Phil.	External Examiner
2016	Department of Anatomical and Cellular Pathology. CUHK	Lie, Rosalind	M.Phil.	External Examiner
2019	Department of Life Science, HKUST	Dai, Yimei	Ph.D.	External Examiner
2019	Department of Paediatrics, CUHK	Zhang Chi	Ph.D.	External Examiner
2019	School of Biomedical Sciences CUHK	Zhang Chenzi	Ph.D.	External Examiner
2020	Department of Anatomical and Cellular Pathology. CUHK	Cheung, Hing Yau Coty	Ph.D.	External Examiner

Internal examiners or chairman of thesis examining committee

Date	Institution	Students	Degree	Role
2004	Department of Pathology	Mohammed Toseef Ansari	M.Phil.	Chairman
2007	Department of Pathology	Hu Xiaotong	Ph.D.	Internal Examiner
2007	Department of Biochemistry	Wong Pui Man	M.Phil.	Internal Examiner
2007	Department of Pathology	Sun Qian	Ph.D.	Chairman
2007	Department of Medicine	Fok Wing Shan Elaine	MRes[Med]	Internal Examiner
2007	Department of Medicine	Ho Lok Yan	MRes[Med]	Internal Examiner
2007	Department of Pathology	Tsang Hon Man	Ph.D.	Internal Examiner
2008	Department of Surgery	Kok Tsz Wai	Ph.D.	Chairman
2008	Department of Microbiology	Huang Yi	Ph.D.	Additional Examiner
2008	Department of Orthopaedics	Chan Chun Wai	M.Phil.	Chairman
2008	Department of Biochemistry,	Chan Wing Yu, Tori	Ph.D.	Internal Examiner
2008	Department of Pathology	Wong Ting Yan Cybil	MMedSc	Internal Examiner
2009	Department of Engineering	Ms. Chiu Wai, Yeung	Ph.D.	Internal Examiner
2008	Department of Paediatrics and Adolescent Medicine	Fung Kwong Lam	M.Phil.	Internal Examiner
2008	Department of Pathology	Hui Chi Ho	MMedSc	Internal Examiner
2009	Department of Microbiology,	Mr. Chan Che Man	Ph.D.	Internal Examiner
2009	Department of Paediatrics and Adolescent Medicine	Mr. Tong Pak Ho	Mphil	Chairman
2010	Department of Pathology	Mr. Wai Kwong Yau	MMedSc	Internal Examiner
2010	Department of Pathology	Ms Wai Kei Fung Vicky	MMedSc	Internal Examiner
2010	Department of Pathology	Mr. Siu Yung Leung	MMedSc	Internal Examiner
2010	Department of Pathology	Ms. Lau Kin Chong	PhD	Chairman
2011	Department of Surgery	Ms. Kam Ka Man	Ph.D.	Internal Examiner
2011	Department of Paediatrics and Adolescent Medicine,	Ms Ye Jieyu	Ph.D.	Chairman
2011	Department of Pathology	Ms Siu Long Kei	MMedSc	Internal Examiner
2011	Department of Mechanical Engineering	Ms Wong Mei Yi	M.Phil	Internal Examiner

2012	Department of Paediatrics and Adolescent Medicine	Ms Hui Kwai Fung	Ph.D.	Chairman
2012	Department of Anatomy	Mr. Wong Kwong Kwan	MMedSc	Internal Examiner
2012	Department of Pathology	Mr. Leung Kin Sang	MMedSc	Internal Examiner
2012	Department of Pathology	Mr. Lam Lap Fung	MMedSc	Internal Examiner
2012	Department of Pathology	Ms. Tsang Tsui Ying Stella	Ph.D.	Internal Examiner
2012	Department of Pathology	Mr. Lui Wing Chi	Ph.D.	Internal Examiner
2012	Department of Medicine	Ms Zhang Jiao	Ph.D.	Internal Examiner
2013	Department of clinical oncology	Ms Qinghui Hui	M.Phil.	Chairman
2013	Department of Paediatrics and Adolescent Medicine	Ms Jian Liang Chen	Ph.D.	Internal Examiner
2013	Department of Paediatrics and Adolescent Medicine	Ms Yuen Ying Leung	M.Phil.	Internal Examiner
2013	Department of Medicine	Ms Haijing Wu	Ph.D.	Internal Examiner
2013	Department of Paediatrics and Adolescent Medicine	Ms (Prof. YF Cheung)	Ph.D.	Chairman
2014	Department of Biochemistry	Ms Shen Yun	Ph.D.	Internal Examiner
2015	Department of Biochemistry	Ms Dai Ying	Ph.D.	Internal Examiner
2015	Department of Paediatrics and Adolescent Medicine	Ms Wing Yi Vivian Li	M.Phil.	Chairman
2015	Department of Paediatrics and Adolescent Medicine	Dr. Joseph Delano Fule Robles	Ph.D.	Internal Examiner
2015	Department of Microbiology	Mr. Li Can	Ph.D.	Internal Examiner
2015	Department of Paediatrics and Adolescent Medicine	Mr. Po Ling Yeung	M.Phil.	Chairman
2015	Department of Microbiology	Ms. Li Can	Ph.D.	Internal Examiner
2017	Department of Medicine	Dr Chi Yuen Cheung, Simon	M.D.	Internal Examiner
2017	Department of Medicine	Dr. Pak Hei Chan	M.D.	Chairman

RESEARCH GRANTS

External Competitive Research Grants as Principal Investigator SINCE 2012

Project Code/Funding Scheme	Project Title/Principal Investigator/Department	Approved Amount (HK\$)	Project Status
Health@InnoHK, Innovation and Technology Commission of the HKSAR	Centre for Oncology and Immunology (I am the key programme leader in haematologic malignancy)	501,000,000 (Total Funding Ceiling)	On-going
T12-702/20-N Theme-based Research Scheme.	Towards personalized and innovative treatment for acute myeloid leukaemia	46,667,000	On-going
HKU17126117	Follistatin as a novel target and biomarker for acute myeloid leukaemia (AML) carrying internal tandem duplication (ITD) of Fms-Like Tyrosine kinase 3 (FLT3).	1,229,089	On-going
04152326 Health and Medical Research Fund	Targeting DNA damage and repair mechanism in FLT3-ITD acute myeloid leukaemia (AML) - a mechanistic and therapeutic study	1,200,000	On-going
Croucher Senior Medical Research Fellowships	Develop a high throughput platform for personalized treatment of acute myeloid leukaemia	4,288,400	On-going
03144046 Health and Medical Research Fund	Establish a zebrafish model to study the molecular and clonal heterogeneity and develop personalized treatment in FLT3-ITD+ AML	1,159,608	On-going
2151209 S.K. Yee Medical Foundation	Provision of free next generation sequencing (NGS) service of prognostic and therapeutic values for patients with acute myeloid leukemia in Hong Kong	1,836,000	On-going
HKUST5/CRF/12R Collaborative Research Fund (CRF) - Group Research Project	Study of Microglia and Myeloid Leukemia in Zebrafish	350,000	On-going
CityU9/CRF/13G Collaborative Research Fund (CRF) - Group Research Project	Development of Cell Manipulation Tools for Probing Functional Mechanism of Hematopoietic Cells: Robotics, Optical tweezers, and Hematopoiesis	1,300,000	On-going
210213 S.K. Yee Medical Foundation	Provision of free sorafenib for patients with refractory or relapsed acute myeloid leukemia to bridge them to curative bone marrow transplantation	600,000	On-going
HKU771613 General Research Fund	A novel role of ADP-ribosylation factors-like 4a (arl4a) in definitive hematopoiesis	909,334	On-going

External Competitive Research Grants as Principal Investigator BEFORE 2012

Project Code/Funding Scheme	Project Title/Principal Investigator/Department	Approved Amount (HK\$)	Project Status
HKU 771611M General Research Fund (GRF)	Is sox7 a tumour suppressor in acute myeloid leukemia?	1,050,000	Completed
HKUST6/CRF/09 Collaborative Research Fund (CRF) - Group Research Project	Study of Microglia and Acute Myeloid Leukemia in Zebrafish	400,000	Completed
HKU 771110M General Research Fund (GRF)	A novel role of methionine aminopeptidase 2 (MetAP-2) in the regulation of hematopoietic stem cell during definitive hematopoiesis	887,400	Completed
CityU 120310E General Research Fund (GRF)	Robotic Manipulation of Biological Cells with Optical Tweezers	200,000	Completed
210213 S.K. Yee Medical Foundation - General Award	Provision of free sorafenib for patients with refractory or relapsed acute myeloid leukemia to bridge them to curative bone marrow transplantation	600,000	Completed
209214 S.K. Yee Medical Foundation - General Award	Provision of free molecular tests for patients with acute myeloid leukemia with normal cytogenetics	631,536	Completed
HKU 769809M General Research Fund (GRF)	Is aldehyde dehydrogenase a negative regulator of primitive hematopoiesis during embryonic development?	1,100,000	Completed
08070552 Research Fund for the Control of Infectious Diseases	Detection of WU and KI polyomaviruses from patients with acute respiratory tract infections in Hong Kong	799,544	Completed
208203 S.K. Yee Medical Foundation	Provision of free service for serum polyoma BK virus quantification to kidney transplant recipients in Hong Kong	692,700	Completed
HKU 770308M General Research Fund (GRF)	Is Jak2V617F mutation a stem cell event in chronic myeloproliferative disease?	1,383,247	Completed
207215 S.K. Yee Medical Foundation	Provision of free alemtuzumab (anti-CD52) to patients with chronic lymphocytic leukemia refractory to conventional chemotherapy	611,288	Completed

HKU 7520/06M General Research Fund (GRF)	The roles of survivin in hematopoiesis, angiogenesis and tumorigenesis in a zebrafish knock-down and transgenic model	1,032,500	Completed
HKU 7488/04M General Research Fund (GRF)	A study of normal and deregulated haematopoiesis in zebrafish, with special reference to the role of BMP signaling in haematopoietic stem cell proliferation	1,525,920	Completed

External Competitive Research Grants as co-investigator

Project Code/Funding Scheme	Project Title/Principal Investigator/Department	Approved Amount (HK\$)	Project Status
C7028-19G Collaborative Research Fund (CRF)	Integrative chemical biology approaches to decipher histone marks on H3K79	1,000,000	On-going
03143756 Health and Medical Research Fund	Generating transgenic zebrafish model to study the emerging role of autophagy and mitophagy in hematopoietic diseases (PI: Dr CH Ma, Dept of Health and Informatics, HK Polytechnic University)	1,138,440	On-going
C7018-14E Collaborative Research Fund (CRF) - Major Equipment Project	Micro-PET for pre-clinical molecular imaging research in Hong Kong (PI: Professor PL Khong, Dept of Diagnostic Radiology, HKU)	4,000,000	On-going
02132326 Health and Medical Research Fund	Developing an in vivo zebrafish platform for functional evaluation of recurrent mutations in acute myeloid leukemia (AML) and primary screening of novel targeted therapeutic agents (PI: Dr CH Ma, Dept of Health and Informatics, HK Polytechnic University)	998,440	On-going
210209 S.K. Yee Medical Foundation	Provision of clofarabine for the treatment of relapsed or refractory acute leukaemia (PI: Professor YL Kwong, Dept of Medicine, HKU)	600,000	On-going
17118914 General Research Fund (GRF)	Mechanisms of leukaemic transformation from myelodysplastic syndromes (MDS) failing treatment with demethylating agents. (PI: Dr GHH Singh, Dept of Medicine, HKU)	835,546	On-going
213225 S.K. Yee Medical Foundation	Provision of free azacitidine for high-risk patient with myelodysplastic syndrome (MDS) (PI: Professor YL Kwong, Dept of Medicine, HKU)	1,792,000	On-going
HKU 768313M General Research Fund (GRF)	Efficacy and safety of a novel intradermal live-attenuated varicella zoster vaccine in hematopoietic stem cell transplantation	691,267	On-going

212208 S.K. Yee Medical Foundation	donors: a randomized double-blind placebo-controlled trial (PI: Professor FNI Hung, Dept of Medicine, HKU) Provision of bendamustine for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (PI: Professor YL Kwong, Dept of Medicine, HKU)	1,095,680	On-going
HKU 7651/05M General Research Fund	The role of telomerase in protecting retinal ganglion cells against axonal injury (PI: Dr HKF Yip, Dept of Anatomy, HKU)	1,271,914	Completed
HKU 7548/05M General Research Fund	Effects of all-trans retinoic acid (ATRA) on stromal cells and haematopoietic stem cell engraftment (PI: Professor R Liang, Dept of Medicine, HKU)	585,957	Completed
HKU 7443/03M General Research Fund	Adoptive transfer of herpes zoster cellular immunity to BMT patients by vaccination of seropositive donors with live-attenuated varicella zoster vaccine (PI: Professor R Liang, Dept of Medicine, HKU)	624,000	Completed
HKU 7270/97M General Research Fund	Developing a cytotoxic T-lymphocyte precursor (CTLP) based assay for Graft-versus-Leukaemia (GVL) effect (PI: Professor R Liang, Dept of Medicine, HKU)	500,000	Completed

Internal Research Grants as Principal Investigator

Project Code/Funding Scheme	Project Title/Principal Investigator/Department	Approved Amount (HK\$)	Project Status
Seed Funding for Strategic Interdisciplinary Research Scheme	A Comprehensive and Multidisciplinary Approach Targeting Acute Myeloid Leukaemia in Hong Kong	1,858,000 + one post-doctoral fellow	Completed
200611159101 Seed Funding Programme for Basic Research	The roles of Jak2a in primitive hematopoiesis during embryonic development using zebrafish as a model	80,000	Completed
200711159060 Seed Funding Programme for Basic Research	The role of aldehyde dehydrogenase in primitive hematopoiesis during embryonic development	106,000	Completed
200602160010 Seed Funding Programme for	Establish a blood cancer model of polycythemia vera in zebrafish to	100,000	Completed

Applied Research	facilitate drug screening targeting at Jak2 activation		
Small Project Funding	Ex-vivo expansion of haematopoietic stem cells derived from human umbilical blood with special reference to the effects of all-trans retinoic acid (ATRA)	68,000	Completed
Small Project Funding	Adoptive transfer of cellular immunity to herpes zoster in BMT patients by vaccinating their seropositive donors with live-attenuated varicella zoster vaccine	87,900	Completed

Internal Research Grants as co-Investigator

Project Code/Funding Scheme	Project Title/Principal Investigator/Department	Approved Amount (HK\$)	Project Status
201509159007 Seed Fund for Basic Research	Mechanisms of resistance in acute promyelocytic leukaemia failing treatment with oral arsenic trioxide (PI: Dr GHH Singh, Dept of Medicine, HKU)	43,000	Completed
201501159011 Seed Fund for Basic Research	Role of Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in relapsed acute promyelocytic leukaemia (APL) treated with oral arsenic trioxide (PI: Dr GHH Singh, Dept of Medicine, HKU)	120,000	Completed
201401159004 Seed Fund for Basic Research	The role of inka1b in zebrafish hematopoiesis (PI: Dr CH Ma, Dept of Medicine, HKU)	120,000	Completed
201205159002 Seed Fund for Basic Research	Dissecting Variable Chemotherapeutic Drug Sensitivities in Human Acute Myeloid Leukemia (AML) Based on Differential Signalling Profiles (PI: Dr AMS Cheung, Dept of Medicine, HKU)	120,000	Completed
Queen Mary Hospital Charitable Trust - Training and Research Assistance Scheme	Correlation of the AML1-ETO isoform transcript levels with the prognosis of patients with acute myeloid leukemia (AML) with t(8;21) (PI: Dr WL Choi, Dept of Pathology, HKU)	22,500	On-going
200907176072 Small Project Funding	Which aldehyde dehydrogenase isoform(s) is	53,333	Completed

200807176190 Small Project Funding	are important for primitive hematopoiesis during zebrafish embryonic development (<i>PI: Dr CH Ma</i> , Dept of Medicine, HKU) The role of NUP98 in hematopoiesis in zebrafish and generation of zebrafish model for NUP98-HOXA9 overexpression (<i>PI: Dr TK Fung</i> , Dept of Medicine, HKU)	54,502	Completed
TRAS-08-03 (01/13/109) Queen Mary Hospital Charitable Trust - Training and Research Assistance Scheme	Retrospective study on prevalence and prognostic significance of c-kit mutation in AML1-ETO acute myeloid leukemia (AML) (<i>PI: Dr WL Choi</i> , Dept of Pathology, HKU)	30,000	Completed
200611159093 Seed Fund for Basic Research	The roles of aldehyde dehydrogenase 1A1 (ALDH) in defining and regulating leukemia initiating cell activity in acute myeloblastic leukemia (<i>PI: Emeritus Professor R Liang</i> , Dept of Medicine, HKU)	100,000	Completed

Research awards and prizes

Years	Awards
2018	Outstanding Research Supervisor Award HKU
2017	Faculty Outstanding Research Output Prize
2016	Croucher Senior Medical Fellowships
2014	Li Shu Fan Foundation Professorship in Haematology
2001-2003	Croucher Fellowships
2003	Best Dissertation Award, Hong Kong College of Physicians (Bronze)
2002	Outstanding Research Paper Award, Hong Kong College of Physicians
1993	Young Scholar Award for the best Ph.D. thesis. The Chinese University of Hong Kong
1992-1993	Sir Edward Youde Memorial Fellowships

KNOWLEDGE EXCHANGE

Knowledge transfer via lectures to professional and academic institutions outside HKU

Lecture Title	Meeting	Time
Post Bone Marrow Transplant Complication and Management	Certificate Course for Clinical Haematology Nursing in PMH	2007
Management of clients with abnormal complete blood picture	The Family Planning Association of Hong Kong	2007
Common Haematological Problems in ICU - from bench to bedside	Intensive Care Unit, Queen Elizabeth Hospital, Kowloon, Hong Kong	2008
Disseminated Intravascular Coagulopathy and Blood components & Massive blood transfusion	School of General Nursing	2010
Overview of BMT and apheresis	HA IANS and CUHK	2011
Extracorporeal photopheresis and haematopoietic stem cell mobilization	PRCC course in haematology nurses	2015
Effective patient blood management in haemato-oncology patients	Central Committee (Transfusion Service). HA Commissioned Training.	2015

Invited lectures to general public

1. 香港大學李嘉誠醫學院與香港公共圖書館合作舉辦 (2010): 幹細胞的研究與應用
2. 心血會: 淋巴瘤最新治療方法講座 2008
3. 心血會: 淋巴瘤最新治療方法講座 2011
4. 心血會: 骨髓移植知多少 2015

TEACHING AND LEARNING

Undergraduate teaching load (hours per year) since 2017/2018

Activities include whole-class teaching, small group tutorial, bedside tutorial and discussion, teaching clinic as well as MBBS examinations.

2017-2018: 102

2018-2019: 105


2019-2020: 85.25

SETL Scores since 2017/2018

Formal lectures

2017/2018: MBBS IV (6-yr) Junior Clerkship Whole Class Session - Lecture 43 and 49

All aspects considered, the teacher was effective in helping me achieve the course learning outcomes.




Overall	Total Forms Distributed:	20090
	Total Forms Returned:	9438
	Response Rate:	46.98%
This Group	Total Forms Distributed:	205
	Total Forms Returned:	96
	Response Rate:	46.83%

- 5: Strong Agree
- 4: Agree
- 3: Neutral
- 2: Disagree
- 1: Strongly disagree

Students' Comment: Very clear and effective teaching

2018/2019: MBBS IV (6-yr) Junior Clerkship Whole Class Session - Lecture 43 and 49




Overall	Total Forms Distributed:	21879
	Total Forms Returned:	9983
	Response Rate:	45.63%
This Group	Total Forms Distributed:	221
	Total Forms Returned:	108
	Response Rate:	48.87%

- 5: Strong Agree
- 4: Agree
- 3: Neutral
- 2: Disagree
- 1: Strongly disagree

Students' Comments: Highly appreciated for the additional lecture; He was very clear in his teaching and the content was very clinically relevant.

2019/2020: MBBS IV (6-yr) Junior Clerkship Whole Class Session - Lecture 43 and 49



Overall	Total Forms Distributed:	21850
	Total Forms Returned:	7228
	Response Rate:	33.08%
This Group	Total Forms Distributed:	230
	Total Forms Returned:	83
	Response Rate:	36.09%

- 5: Strong Agree
- 4: Agree
- 3: Neutral
- 2: Disagree
- 1: Strongly disagree

Students' comments: Very clear; Prof Leung was very nice to answer any questions related to haematology, as well as provide clear classifications of the different diagnosis for anaemia and lymphadenopathy. It was also good of him to provide a few questions for consolidation; Cleared a lot of concepts! Very clear slides and presentation, lecturer is also very helpful; Clear and informative; Well structured and highly engaging. Thank you Prof Leung for encouraging us to ask questions. We especially enjoyed the cases illustration at the end to help us test our understanding better; Professor Leung's lectures are engaging and very memorable. He is also very patient in answering questions after the lecture; awesome.

Specialty Clerkship (Medicine-Related Block 2017)

Rotation 1:

Bedside PBL: Number of responses: 16 students

My score: 92.19; Average score: 88.89

Students' comments: He had a clear outline for his teaching from presentation, differential diagnosis, workshop to management for topics that were less covered in large group teachings. 2. Very Good.

Rotation 2:

Number of responses: 16 students

My score: 87.50; Average score: 89.68

Rotation 4:

Number of responses: 8 students

My score: 90.63; Average score: 83.04

Rotation 4:

Teaching clinic; Number of responses: 22 students

My score: 87.50; Average score: 83.24

Rotation 5:

Bedside PBL: Number of responses: 12 students

My score: 91.67; Average score: 89.50

Students' comments: 1). Excellent tutorials 2). Prof Leung is very kind and responsible that he offered us extra tutorial even after the 2 sessions. 3). Prof Leung arranged an extra session for us to ask questions on

haematology, he is very helpful and willing to teach. 4). Very good and clear illustration of learning point, excelling teacher to explain the pitfall and misunderstanding of students

Rotation 7:

Bedside PBL: Number of responses: 20 students

My score: 95; Average score: 91.18

Students' comments: i. Very good teaching session, learnt a lot! ii. Excellent.

Specialty Clerkship (Medicine-Related Block 2018)

Rotation 1:

Number of responses: 16 students

My score: 78.13; Average score: 88.98

Rotation 3:

Teaching clinics: Number of responses: 13 students

My score: 88.46; Average score: 85.55

Students' comments: Very detailed explanation; Willing to answer questions

Rotation 4:

Number of responses: 6 students

My score: 91.67; Average score: 88.25

Rotation 5:

Friday new case OPD: Number of responses: 15 students

My score: 88.33; Average score: 81.24

Students' comments: Very good teaching and clearly told us the main learning points.

Rotation 6:

Number of responses: 4 students

My score: 100; Average score: 88.60

Rotation 6:

Teaching Clinics: Number of responses: 5 students

My score: 90; Average score: 88.07

Rotation7:

Bedside PBL: Number of responses: 17 students

My score: 100; Average score: 86.64

Students' comments: Extremely useful.

Specialty Clerkship (Medicine-Related Block 2019)

Rotation 1:

Number of responses: 13 students

My score: 96.15; Average score: 91.98

Rotation2:

Bedside PBL: Number of responses: 8 students

My score: 96.88; Average score: 85.62

Students' comments: Very structural and sensible way to teach haematology 2) Excelling teaching on various haem topics. 3) Clear & essential

Rotation 3:

Teaching clinic: Number of responses: 25 students

My score: 96; Average score: 84.85

Students' comments: 1) Very informative and practical lecture on blood transfusion and it's complication. Very clear explanation 2) Although the topic was quite difficulty per se. Prof Leung has given us a very clear and easy-understandable teaching with thorough explanations. 3) Excellent teaching 4) Excellent

teaching 5) Very practical and on-point 6) Extremely patient to explain complex hematological concepts to students

Rotation 4:

Number of responses: 7 students

My score: 92.86; Average score: 82.53

Students' comments: Great teaching!

Rotation6:

Grand Round: Number of responses: 24 students

My score: 76.34; Average score: 76.19

Rotation7:

Case discussion: Number of responses: 10 students

My score: 91.07; Average score: 88.87

Specialty Clerkship (Medicine-Related Block 2020)

Rotation 1:

Emergency round, Number of responses: 5 students

My score: 86.43; Average score: 86.43

Friday new case OPD, Number of responses: 8 students

My score: 84.82; Average score: 76.91

Rotation 2:

Case discussion, Number of responses: 6 students

My score: 94.05; Average score: 88.12

Comments from Students before 2017:

Specialty Clerk 2013 Teaching Clinic Rotation 3

Well taught! Could have provided notes for us before lecture!

MBBS III Junior Clerk Rotation 1 2013-2014

Prof AYH Leung – very detailed explanations and willing to go overtime of the session to answer questions and teach

MBBS III Junior Clerk Rotation 3 2013-2014

Professor AYH Leung is very good interactive tutor, he not only talk about things related to the cases, but he also taught us some extra useful knowledge.

MBBS III Junior Clerk Rotation 2 2014-2015

Precise and simple, fulfill student's need; Precise.

Specialty Clerk 2014 Rotation 2 Teaching Clinic

(1) Very hilarious and easy going, enjoy his lesson very much. Should come back to teach more often!

(2) Very concise & practical

Senior Clerk Rotation 2 2013-2014

Teaching clinic: The material presented is very useful. Could consider distributing to students for better learning outcome.

The hematology teaching clinic delivered by Prof AYH Leung was excellent. It was memorable and intellectually stimulating. On a side note Prof Leung's bedside teaching was also brilliant. He should engage in more teaching activities and inspire more students.

As mentioned in another evaluation page, Prof AYH Leung's hematology teaching clinic was excellent.

Specialty Clerk 2014 Rotation 2

OPD: (1) Appreciate Prof Leung's teachings on the systemic approach on diseases; (2) Very good teaching and super supportive

Specialty Clerk 2014 Rotation 3

Case discussion: I found this teaching really useful as he discussed the case with us in CCT format. He discussed the case thoroughly and told us the approach for each.

Specialty Clerk 2014 Rotation 4

PBL: Very good sessions with Prof Leung, very enthusiastic in teaching, and made all understand the scope of haematology

Specialty Clerk 2014 Rotation 6

PBL: Extremely fruitful PBL. Prof Leung should teach more sessions. OPD: Prof Leung is very inspiring, teaches amazingly well.

Specialty Clerkship 2015 Rotation 1

Prof Leung was very willing to teach and very helpful in grading our learning objectives in relation to our cases. He also ensured that our foundations were solid by giving a quick revision session on the basics Professor AYH Leung is extremely helpful and was able to give us an extra tutorial session to help Better understand concepts of haematology. A very passionate teacher!

Specialty Clerk 2015 Rotation 4

OPD: Good

Leaderships in teaching and learning at post-graduate levels

1. Accredited PACES (Practical Assessment of Clinical Examination Skills) Examiner (Since 2013-)
Duties: Examine postgraduate physician trainees in HK in PACES examination twice annually (on average one day per diet)
2. Member, MRCP Part I Board (2013-2018)
Duties: Quality assurance of examination questions (haematology specialist) for Part I MRCP(UK) in UK and other overseas centres. Three meetings per year in London, Glasgow and Edinburgh.
3. Assistant Programme Director, Hong Kong College of Physicians (HKCP) (2011-2016)
Duties: Monitoring of basic physician training and assessment in Hong Kong West Cluster
4. Chairman of Examination Committee, Hong Kong College of Physicians (HKCP) (2014-2019)
Duties: Chief coordinator between HKCP and Royal College of Physicians (UK) in the organization of PACES examinations which are held twice annually in 10 HA Hospitals. PACES examination is the prerequisite for basic physician trainees to register for any specialist training programme in HK.
5. Secretary, Haematology and Haematological Oncology Board, HKCP (Since 2016-2019)
Duties: Organize training and assessment for all haematology specialist trainees in HK
6. Chairman, Haematology and Haematological Oncology Board, HKCP (2019-2020)
Duties: Coordinate training and assessment for all haematology specialist trainees in HK

Supervision of undergraduate Science Students

Principal supervisor of students majoring in Biochemistry in their Final Year Projects

2007-2008: August K.P. Fan (HKU). Project: Zebrafish jak2a/stat5.1 mediated primitive hematopoiesis – when and how?

2009-2010: Alan L.T. Chan (HKU). Project: A study of zebrafish hematopoiesis

2009-2010: Victor C.H. Au (HKU). Project: Investigating the effects of inhibiting MetAP-2 by fumagillin in leukemia

2011-2012: Murphy K.H. Sun (HKU). Project: Cytokine profiling in acute myeloid leukemia

2012: Ma Shuo (Han University, The Netherlands). Project: pH regulation in acute myeloid leukaemia

2017: Yang Yang (Han University, The Netherlands). Project: Protein synthesis inhibition as therapeutic target for acute myeloid leukaemia.

Curriculum Development

Departmental Level

2004-2008	Convenor of the Final Year Special Study Modules
2007-2012	Departmental Coordinator, Specialized Field of Study in MEDI6100 Introduction to Stem Cells (formerly Cancer Genetics) of the MMedSc Programme
2008-2012	Junior Clerkship BlkA Deputy Coordinator, Year 3 coordinating sub-committee
2011-2015	Member, Undergraduate Committee (Assessment and Evaluation)

Faculty Level

2004-2008	System coordinator of MBBS (II) Haematology/Immunology Block
2008-2012	Board of Examiners, Master of Medical Sciences (MMedSc)
2008-2015	Coordinator, M.Res.Med Program
2009	Coordinator (AoI: Science and Technological Literacy), Common Core Curriculum

University Level

Since 2010-	One of the key teachers of the Common Core Curriculum course entitled: "Stem Cells: Promises, concerns and uncertainties"
-------------	---

ADMINISTRATION AND LEADERSHIPS

Faculty Level

2015-2018	Associate Dean (Human Capital)	LKS Faculty of Medicine
2016-	Member	Promotion and Tenure Panel, LKS Faculty of Medicine
2008-2015	Assistant Dean (Research)	LKS Faculty of Medicine
2008-2015	Chairman	Board of Studies of the Master of Research in Medicine
2008-2015	Chairman	Board of Examiners of the Postgraduate Diploma in Infectious Diseases
2008-2015	Chairman	Board of Examiners of the Postgraduate Diploma in Diagnosis and Therapeutics in Internal Medicine
2013-2016	Deputy Director	Centre of Reproduction, Development and Growth
2012	Chairman	Organizing Committee, Frontiers in Biomedical Research, LKS Faculty of Medicine
2009 – 2011, 2013	Deputy Chairman	Organizing Committee, Frontiers in Biomedical Research, LKS Faculty of Medicine
2008-2010	Member	Faculty Review Committee
2008-2015	Member	Board of Studies of the Master of Public Health Postgraduate Diploma & Postgraduate Certificate in Public Health
2008-2015	Member	Board of Examiners of the Master of Research Medicine
2008-2015	Member	Board of Studies of the Postgraduate Diploma in Infectious Diseases
2008-2015	Member	Board of Studies of the Postgraduate Diploma in Diagnosis and Therapeutics in Internal Medicine
2009-2015	Member	Management Committee, Centre of Reproduction, Development and Growth
2010-2015	Member	Faculty Subcommittee for appointment of Honorary Senior Teachers
2006	Member	Organizing committee member of the Stem Cell Workshop. Strategic Research Theme of Development and Reproduction.
2006	Member	Organizing committee member of the Stem Cell Retreat. Strategic Research Theme of Development and Reproduction.

Departmental Level

2009, 2010	Chairman	Organizing committee, Medical Research Conference
2005, 2006, 2008	Member	Organizing committee, Medical Research Conference
2005, 2010	Member	Organizing committee, Medical Forum
2008-Present	Member	Social committee
2019-Present	Deputy Head	Strategies and Development

Community Level

Honorary Advisor, The Hong Kong Bone Marrow Transplant Patients' Association Limited.
2005- Present

Panel Coordinator, Science Museum Exhibition – Discoveries on Reproduction, Development and Growth: from Gamete to Adult 2007

Reviewer for grants / Selection

Since 2009- Internal reviewer for grants submitted to General Research Fund, HKU

Since 2008- HKU/China Medical Board Grants

From 2012- Co-opted member, University Research Committee, HKU